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Purpose/Aims: For adult participants who have received or are receiving treatment for 
hematologic and solid tumor malignancies given orally, this study describes the 
relationship between participants’ experience of financial toxicity (FT), the participants’ 
perception of distress associated with FT, and participants’ self-identified adherence to 
prescribed treatments in the context of FT.  
 
Background:  FT has emerged as an additional source of distress for cancer patients. The 
costs of treatments given orally can be prohibitively expensive for patients. Therefore, 
these patients may experience considerable distress and may not adhere to treatments as 
prescribed. 
 
Method: Descriptive cross-sectional correlational design study of a sample of adult 
cancer patients treated with therapy given orally.  Study data was analyzed using 




Findings: Data from 136 participants included participant perceptions of FT, distress and 
adherence at seven days and six months post start of treatment.   At both timepoints, 
patients had moderate scores for FT, according to COST instrument data.  At both 
timepoints for distress, 39-42% of patients had high distress scores related to FT.  There 
was no correlation between FT and distress.  Responding to specific COST instrument 
questions, 80% or participants responded that they feel they have no choice about the cost 
of care.  At seven days post start of treatment, 67.1% of patients reported that OOP 
expenses were higher than anticipated. At six months post start of treatment 59.4% of 
patients reported that OOP expenses were higher than anticipated.  Most correlations 
among variables were weak with the exception of a strong correlation between help from 
pharmaceutical companies/foundations and percentage of financial help from those 
funding sources (r = .869, p = <.001). Based on data from this sample, FT was not 
established as a predictor of distress or adherence to treatment. 
 
Implications for Nursing: Despite this sample data showing minimal statistically 
significant correlations, FT has clinical significance.  Nurses can mitigate the impact of 
FT on patients and caregivers by including FT assessment as a component of clinical 
assessment, referring patients to healthcare FT experts and resources and providing 
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BACKGROUND and SIGNIFICANCE 
Introduction 
By the year 2026, healthcare spending is expected to account for more than 19% 
of the U.S. economy (Health and Human Services, 2018). And from 2019 estimates, 
healthcare spending is expected to top $4.3 trillion (Schnipper et al., 2016). For the 
consumer of healthcare, the pace of yearly healthcare costs is increasing at a steady clip, 
yet has slowed somewhat in the last few years. For the period 1990-2007, the cost of 
healthcare increased on average 7.3% yearly.  For the period 2017-2026, healthcare 
spending is expected to increase on average 5.5% a year (HHS, 2018). This rise in 
healthcare costs can, in part, be attributable to an aging population—the primary 
consumer of healthcare—and the rise in the cost of prescription and specialty drugs that 
include prescription (non-generic) medications, newly FDA-approved and early in their 
patent period. Therefore, prescription and specialty drugs are more costly than generic or 
standard formulary medications (Bradley et al., 2016; Shih et al., 2015; Davidoff et al., 
2013).   
Contributing to increased healthcare costs, the rise in prescription drugs is 
expected to increase 6.3% yearly (HHS, 2018). With the high cost of healthcare, third-
party private and government health care insurers have transferred more of the burden for 
healthcare costs to patients, specifically through co-payments, deductibles and any out of 
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pocket (OOP) costs not covered by the insurer (Galbraith et al., 2011). Yet those with 
coverage are the lucky ones who at least have some type of healthcare insurance coverage 
despite the limitations of that coverage that increase expenses to the patient (Gaba et al., 
2016; Guy et al., 2013; Guy et al., 2014).   
Further, the expense of annual insurance deductibles for health plans has been 
steadily rising (Claxton et al., 2015). On average in 2017, covered workers contributed 
18% of the premium for single coverage and 31% of the premium for family coverage. 
Since 2012, family coverage premiums have increased 19%. Since 2007, family coverage 
premiums have increased by 55%. (Kaiser Family Foundation, 2017). A study by the 
Kaiser Family Foundation reported only 53% of respondents had household incomes that 
could cover an annual deductible of $2,400.  And when choosing a less robust insurance 
plan with a higher deductible of $5,000 annually, only 45% of respondents could afford 
that expense (Claxton et al., 2015).  
Moreover, for those in treatment for cancer, OOP costs can exceed $5,000 
annually (Bernard, Farr, & Fang, 2011; Davidoff et al., 2016). Significantly, the annual 
medical cost of cancer care was estimated to be $124.6 billion in 2010 and is projected to 
increase to $157.8 billion by 2020 (Mariotto et al., 2011). 
In the context of burgeoning healthcare costs, the concept of financial toxicity 
(FT) has emerged, especially for those diagnosed with cancer (IOM, 2013; Tucker-Seeley 
et al., 2016).  FT can be defined as a constellation of financial challenges for patients.  
These can include high medical payments during or after treatment ends as well as lower 
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income due to job interruption or job loss due to treatment (Zafar & Abernethy, 2013a; 
Delgado-Guey et al., 2015).  
The Commonwealth Fund has estimated that 23% of insured adults have OOP 
healthcare costs that are equivalent to more than 10% of their household income (Ell et 
al., 2008). In 2013, a Medicare Current Beneficiary Survey estimated that 28% of cancer 
survivors reported high OOP expenses compared to 16% with no cancer history 
(Davidoff et al., 2013).  Moreover, individuals covered by public insurance report high 
proportional OOP expenses, especially when those individuals cannot work due to 
illness.  
In a 2014 report, the Center for Diseases Control (CDC) estimated annual 
healthcare expenses and related productivity losses for male survivors of cancer to be 
$4,187, an estimated $1,459 more than those without a history of cancer. For female 
survivors of cancer, FT had sustaining effects with their estimated annual healthcare 
expenses and related productivity loss at $3,293 compared to those without a history of 
cancer, estimated at $1,330 (Ekwueme et al., 2014). In a 2016 Medical Expenditure Panel 
Survey of 1,202 cancer survivors, an average 20.4% of these survivors reported financial 
hardship associated with their cancer or treatment and extended period of recovery. From 
this sample of patients, 7.1% reported borrowing to pay their bills or go into debt, and 
almost 12% of patients reported they were unable to cover their OOP costs and that led to 
psychosocial hardship (Yabroff et al., 2016).   
Therefore, the concept of FT and its impact on cancer patients has gained 
visibility and parity with other treatment side effects that require management (ASCO, 
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2018; Delgado-Guey et al., 2015). FT, as an unwanted side effect from cancer treatment, 
has been shown to affect cancer patients in treatment with similar distress as other side 
effects or toxicities from cancer treatment such as fatigue, nausea and vomiting, anxiety 
and sleep disturbance (Bestvina et al., 2014; Delgado-Guay et al., 2015; Ubel et al., 
2013). A study of 300 cancer patients in treatment reported that 39% of them experienced 
greater financial burden from their care than they expected and 19% stated they were 
overwhelmed due to financial distress (Chino et al., 2017). According to a systematic 
review of studies about cancer patients and financial distress, an estimated 28-73% of 
cancer survivors report FT (Gordon et al., 2017). 
Cancer Care: Advances in Treatments 
This is a time of breakthroughs in the treatment of cancer, which include the 
promise of molecular and genetic-based treatments for those diagnosed with hematologic 
or solid tumor malignancies. As additions to multi-modality approaches to treat cancer, 
these new therapies are advancing the number of treatment options available to patients. 
These treatments can further refine the precision of prescribed treatments since they are 
based on the patient’s own genetic and metabolic profile (Haslem et al., 2018). In part 
due to these breakthrough treatments, in the U.S. cancer continues to be one of the most 
expensive and difficult health challenges to treat (Bradley et al., 2016; Andrews, 2015). 
Treatments for cancer have included surgery, radiation therapy, chemotherapy 
and biologics therapies, either alone or in combination (Shih et al., 2015; Nair & Kong, 
2018).   With the addition of targeted therapies—many of them formulated in an oral 
form—some cancer patients can take a pill to treat their cancer rather than the 
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operationally-complex treatments of surgery, radiation or infusion chemotherapies 
(Haslem et al., 2018: Nair & Kong, 2018).  Moreover, advances in molecular biology and 
genetics have expanded these cancer treatment options given orally, with these treatments 
becoming a frequent source of FT (Bayer et al., 2017; Ginex et al., 2017). Although such 
targeted treatments given orally have been shown to be more effective and easier to 
tolerate (Garraway et al., 2013), OOP copayment costs to the patient can be staggering, 
even when insurance pays a large component of the treatment cost (McNulty & Khera 
2015; Meisenberg, 2015).  
Cancer Treatment and Cost 
Targeted therapies in oral form, developed from extensive and often prolonged 
clinical trials by pharmaceutical companies and academic facilities, can be very 
expensive. A 1995-2013 analysis of 58 approved anticancer drugs reported that adjusted 
for inflation, the costs of these drugs increased annually by 10% or approximately $8,500 
a year (Howard et al., 2015). Mariotto and colleagues estimated that by 2020, the cost of 
cancer care in the U.S. that includes these pricey cancer treatments will be almost $158 
billion (using models that account for incidence, survival and cost). This is a 27% 
increase over estimates of the cost of cancer care from 2010 (Mariotto et al., 2011).  
Even if a third-party payor provides coverage of these treatments and supportive 
therapies, the OOP cost to the patient can be steep (ASCO, 2018).  In a 2017 analysis of 
insurance coverage, 57% of employees with single (non-family) coverage by employer-
supported insurance had an annual OOP maximum of more than $3,000. And another 
18% had an OOP maximum of more than $6,000 (KFF, 2017). And patients may not 
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know the OOP cost of these treatments until well after treatment starts since the amount 
of the OOP costs for these treatments can vary depending on insurance coverage, facility 
discounts with the medication manufacturer and/or pharmaceutical or patient advocacy 
assistance programs (Zafar et al., 2103a, 2013b; Zafar et al., 2013c; Zafar, 2016; 
Henrikson, & Shankaran, 2016).   
In addition, studies show that oncologists are reluctant to bring up the cost of 
medications with patients due to a variety of factors, such as not knowing the cost of the 
medication themselves, limited data on the clinical value (outcomes based on quality of 
life and survivorship), and the patients themselves not wanting to know the cost 
(Gidwani-Marszowski et al., 2018; Carrera et al., 2018; Tucker-Seeley & Yabroff, 2016). 
In June 2017 in a position statement, the American Society of Clinical Oncology 
(ASCO), the professional organization for clinical oncologists, expressed concern about 
the affordability of oncology specialty drugs due to unaffordable coinsurance rates and 
their OOP expense to the patient (ASCO, 2017). 
The costs of receiving care for cancer extend beyond the OOP costs associated 
with prescription drugs or co-pays. These costs add up. The extra costs of care include a 
constellation of expenses that are in addition to treatment costs. The cost of receiving 
care for cancer includes costs of transportation to and from clinic appointments and 
treatments, parking fees, hotel stays, over the counter medications, child care while in 
treatment, the cost of non-covered second opinions, special diets and other needs. 
Especially for low-income patients, transportation issues are a focus of FT and a primary 
stressor (Massa et al., 2018; Carrera et al., 2018).   
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Moreover, studies estimate that a range of 25-40% of cancer patients are more 
likely to miss work or require reduced work hours while in treatment or recovering from 
declining health (Ferrell et al., 2018; Huntington et al., 2015; Jagsi et al., 2014). A 2017 
systematic review of studies about cancer survivors reported some form of financial 
distress because of the patients’ cancer treatment. Studies included in the review reported 
that survivors’ mean annual productivity loss was $380-$8,236, with 12-62% reporting 
that treatment caused them to be in debt (Altice et al., 2017). A study of cancer patients in 
Washington State reported the bankruptcy risk for the general cancer population at 2.1% 
approximately 2.5 years after cancer diagnosis (Ramsey et al., 2013). 
Financial Toxicity 
In cancer care, the objective and subjective financial consequences of cancer 
treatment may include significant OOP costs, loss of income, and caregiver burden. Since 
2011, the term financial toxicity also has been associated with patients diagnosed with 
cancer who face financial challenges related to precision medicine treatments (Carrera, 
2017; Zhang, Hueser, & Hernandez, 2017). FT is considered akin to hair loss or nausea 
from cancer treatment given the distress that patients feel as a result of experiencing 
financial burden (Carrera et al., 2018). Yet the concept of FT as it relates to patients with 
cancer is not fully understood (Altice et al., 2017; Gordon et al., 2017).  FT as a clinical 
concept lacks standard strategies to screen and measure (Carrera et al., 2018; Gilbert et 
al., 2017). And the ability to pay, especially when related to life-saving treatment, is a 
very personal and individual challenge (Gidwani-Marszowski et al., 2018; Guy et al., 
2015).   These financially-impacted choices can affect when and whether an individual 
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agrees to treatment, the impact of medical expenses on household finances and the impact 
of cancer and treatment on the individual’s quality of life (McNulty & Khera., 2015; Kale 
& Carroll, 2016). 
Sequelae of Financial Toxicity 
In cancer care, with the cost and initial lack of transparency for these OOP costs 
to patients, the care team needs to address and better manage FT (Doyle, 2017). The 
effects of FT create an additional layer of distress for the patient during a time when the 
cancer patient should focus on treatment and management of functional and emotional 
side effects. For the patient, FT-related distress can manifest itself as depression and 
anxiety (Zafar & Abernethy, 2013a, 2013b; 2016; Perrone, et al., 2016). FT has also been 
suggested as a contributing factor to patients not adhering to a costly cancer treatment 
regimen given orally.  
Due to the high OOP costs, some patients just cannot afford the full cost of the 
treatment or decide to partially take the prescribed treatment so they can attempt to 
benefit from some of the treatment effects (Bestvina et al., 2014; Wheeler et al., 2018). 
Few studies have focused on FT as a factor in care delivery--its effect on the patient’s 
adherence to treatment and the wellbeing of patients and their caregivers when patients 
are treated (Bestvina et al., 2014; Kale & Carroll, 2016). 
Study Purpose, Aims and Hypotheses 
For adult participants who have received or are receiving treatment for 
hematologic and solid tumor malignancies given orally, this study will describe the 
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relationship between participants’ experience of financial toxicity (FT), the participants’ 
perception of distress associated with FT, and participants’ self-identified adherence to 
prescribed treatments in the context of FT.  
The aims of this study are: 
1. To describe sociodemographic, clinical and financial characteristics, the 
experience of FT, perception of the level of distress, and adherence to treatment in a 
sample of adult participants who have received or are receiving treatment given orally for 
hematologic or solid tumor malignancies. 
2. To describe relationships between participant sociodemographic, clinical 
and financial characteristics, participants’ experience of FT, participants’ perception of 
distress, and participants’ adherence to treatment.    
Hypotheses:  
• Participant experience of FT will be related to participant perception of distress 
while controlling for statistically significant demographic, financial and clinical 
characteristic covariates. 
• Participant experience of FT will be related to participant adherence to the 
treatment given orally, while controlling for statistically significant demographic, 
financial and clinical characteristic covariates. 
3. To explore the likelihood that participant experience of FT predicts 




• The participant experience of FT predicts the likelihood of participant perception 
of the level of distress. 
• Participant experience of FT predicts the likelihood of participant nonadherence 
to the treatment given orally. 
 
Content of this Dissertation: Overview of Chapters 
As a foundation for this study, Chapter 1 has introduced the concepts of FT as a 
source of distress for cancer patients prescribed treatment given orally. The costs of 
treatments given orally can be prohibitively expensive for patients. Therefore, patients 
may experience distress and may not adhere to the treatments as prescribed. 
Chapter 2 reviews and critiques peer-reviewed literature about FT associated with 
cancer patients receiving therapies orally, patient perception of distress related to FT and 
adherence related to FT.   
Chapter 3 describes the study methods, including the study design, a description 
of the population, protection of human subjects, procedures for recruiting patients, data 
collection procedures, and the plan for statistical analysis.   
Chapter 4 presents the study results organized in order of the study aims. 
Chapter 5 discusses the study findings in the context of clinical practice, 







REVIEW of the LITERATURE  
Introduction 
For patients receiving treatment for hematologic and solid tumor malignancies 
given orally, the purpose of this study is to determine the relationships between the 
patient experience of financial toxicity (FT), patient perception of distress, adherence to 
prescribed treatments and OOP costs of prescribed treatments. This chapter begins with a 
review of the conceptual framework underpinning this study: Carrera’s Conceptual 
Framework of Financial Toxicity in the Treatment of Patients with Cancer (Carrera, 
2017; Kantarjian, & Binder, 2018). The chapter continues with a review of the literature 
as a foundation for the study and specifically addresses cancer treatments given orally, 
the cost of those treatments, cancer treatment and distress, and components of FT for 
patients in treatment for cancer. Finally, the chapter provides a gap analysis, based on the 
literature review, which supports this study’s purpose and aims.   
Conceptual Framework 
The concept of FT has been referred to in the medical literature since 2001. Its 
attributes include a subjective and objective response by cancer patients to the cost of 
their cancer therapies. That response is considered a “hardship” or source of “distress” 
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due to the financial burden that impacts patients, who are already dealing with the impact 
of a cancer diagnoses on their lives (Carrera et al., 2018). 
The research conceptual framework for this study is the Conceptual Framework 
of Financial Toxicity in the Treatment of Patients with Cancer, which is adapted from 
Carrera’s work on the topic (Carrera, 2017; Carrera et al., 2018). The Framework 
presents a foundation for FT, created by a back and forth platform that flows among the 
patient’s expenditures, wealth, anxiety and discomfort. That platform leads to the 
patient’s objective financial burdens, such as the direct costs of treatment and 
expenditures associated with treatment. Examples of the patient’s subjective financial 
burdens are the patient’s perception and experience of financial distress, resulting in 
worry and anxiety about decreased household income and savings (Carrera, 2017; 
Carrera et al., 2018).  
The conceptual framework, Financial Toxicity in the Treatment of Patients with 
Cancer, is shown in Figure 2-1.  Evidence to support the interrelated components of the 
conceptual framework actually begins with early studies about FT by Zafar and 
colleagues, and later studies led by Carrera and Schnipper (Carrera et al., 2018; 
Schnipper et al., 2016).  Zafar and colleagues were the first to publish about FT affecting 
patients’ adherence to treatment.  They also proposed strategies to better approach 
patients’ experience of FT that included having frank and open discussions among 
patients and for health care professionals to take a broader perspective toward treatment 
decisions that go beyond strict clinical guidelines (Zafar, 2016;  Zafar & Abernethy 






Conceptual Framework of Financial Toxicity in the Treatment of Patients with Cancer 
(Used with Permission, John Wiley and Sons: from Carrera et al., 2018) 
 
Based on clinical experience and studies to date, Carrera and colleagues suggest 
that the relationship of costs, expenditures and anxiety are on a continuum, increasing 
discomfort for the patient. They suggest that this level of patient discomfort merits 
effective multidisciplinary approaches to address FT as a toxicity from treatment, just as 
more familiar clinically-based toxicities require attention (Carrera, 2017; Carrera et al., 
2018).   
Addressing the assessment of value of cancer treatment options, Schnipper and 
colleagues have published trailblazing work on behalf of the American Society of 
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Clinical Oncologists addressing FT in clinical care.  This ongoing work discusses FT 
based on value assessment, objective and subjective distress, and shared decision-making 
(Schnipper et al., 2015).  
As represented in this conceptual framework, FT can be associated with the cost 
of newer cancer therapies and with the cost of the therapies (OOP copays and larger 
deductibles), which are more the burden of the patient rather than the insurer (Gordon et 
al., 2017; Altice et al., 2017; Claxton, Rae & Panchal, 2015). 
Therefore, for this study, this conceptual framework suggests relationships 
between the patient’s experience of FT and patient perception of distress (subjective 
burden).  Based on that FT/distress relationship, the framework also serves as a 
foundation for FT-associating patient perception of distress (subjective financial distress) 
and/or patient adherence to prescribed medication (result of objective financial burden). 
Review of Literature 
The literature review was based on peer-reviewed articles, published in English 
from 2010-2018, that were retrieved from these databases: PubMed, CINAHL, OVID and 
Google Scholar. The literature search included the words and phrases, financial distress, 
financial toxicity, patient distress, treatment adherence, cancer oral drugs, cancer 
treatments, oncolytics, cost of cancer care, oral cancer drug prices and OOP cost of 
cancer care.  In addition, the reference list of articles was reviewed for further pertinent 
resources. Approximately 165 articles were reviewed. The review included studies 




Cancer Therapies Given Orally 
This is a period of promising cancer treatment made possible by advances in 
molecular biology, bioinformatics, pharmacometrics and genetic and genomic-
engineering (Maeda & Khatami, 2018). Development of new molecular/genomic 
treatment strategies has been advancing over the past 40 years, with the first Federal 
Drug Administration (FDA)-approved monoclonal antibody treatments for cancer first 
introduced into practice settings in 2000-2005 (Brassil & Ginex, 2018; Bayer et al., 
2017).  
FDA-approved applications for these immunotherapies or so-called targeted 
therapies administered orally have continued at a steady clip, with almost 40 treatments 
approved as of 2018. The rate of these FDA approvals continues with new targeted 
therapies or applications added to therapy options every few months. To support their 
FDA approval, these new treatments given orally must show effectiveness as alternative 
treatment strategies, as additional options to treat frail patients or treatments for those 
who have exhausted standard treatment options (Shih et al., 2015).  Additional 
applications for targeted therapies include more advanced-stage hematologic 
malignancies and more and later-stage solid tumor malignancies (Nair & Kong, 2018; 
Shih et al., 2015). 
Targeted therapies given orally include monoclonal antibodies, cytokine 
therapies, immune checkpoint inhibitors, oncolytic viral therapies and targeted therapies 
(Brassil & Ginex, 2018; Garraway, Verweij & Ballman, 2013). They contribute to the 
future platform for cancer treatment termed precision medicine. These treatments, using a 
scientific development platform called transformational medicine, target the molecular 
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level of cancer cells themselves with specificity to an individual patient’s malignancy, 
rather than reverting to a standard, broad, systematic approach to treatment. The staple of 
standard systemic treatments continues to be chemotherapy or chemotherapy-radiation 
therapy combination treatment protocols (Haslem, Chakaraty & Fulde, 2018; Nair et al., 
2018). 
In addition to precision-medicine treatments given orally, oral formulations of 
supportive therapy—prescribed to lessen or manage treatment side effects—also continue 
to advance in their development.  Examples of these supportive therapies include growth 
factors that reduce cancer treatment-prompted neutropenia (reduced white and red blood 
cell effectiveness and production), anti-nausea and vomiting agents and anti-
inflammatory agents (Irwin & Johnson, 2015).    
Cost of Therapies: Oral Administration 
Insurance coverage of these prescribed oral medications is based upon the 
classification of the pharmaceutical therapy into one of three categories: brand, generic 
and specialty (Hoadley et al., 2015a, 2015b). A brand name medication is a medication 
developed by a pharmaceutical company that holds the patent for the medication and, as 
such, possesses exclusive rights to the manufacturing and sale of the medication. Once a 
patent expires, other companies can produce copies of brand-name drugs, known as 
generic medications, that have the same dosage, intended use, effects, side effects, route 
of administration, risks, safety, and strength as the original drug. Because generic drugs 
are not exclusive to a single manufacturer, they are usually less expensive. A specialty 
medication is a high-cost prescription therapy prescribed to treat complex, chronic 
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conditions (FDA, 2018).  Most cancer treatments given orally, sometimes called 
oncologics, are considered specialty medications. Usually, these specialty medications 
are not included in the formulary of the insurance carrier and as such may not be 
considered a covered medication by the insurer (Hoadley et al., 2015b). In some cases, 
the cost or partial cost of a specialty medication can be covered if the prescriber provides 
clinical justification for the therapy. Whether a specialty medication is a covered benefit 
by the insurer is based on the insurer’s policies, guidelines and discussion with medical 
experts (Carrera et al., 2018; Schnipper et al., 2016). 
Overall, the cost of these oral cancer therapies is exceedingly high. For example, 
in 2015, the annual cost of the oncologic ponatinib, a treatment for chronic myeloid 
leukemia (CML), was an estimated $138,000. As of 2015, the cost of induction (initial) 
treatment for chronic lymphocytic leukemia (CLL) with omacetaxine is $28,000 per year, 
followed by $14,000 annually for maintenance doses. The cost of another oncologic 
agent given orally, bosutinib, is $118,000 per year (McNulty and Khera, 2015).  CLL 
treatment and management is expected to outpace other cancer diagnoses in its costs. 
Figure 2 lists FDA-approved medications as of 2018 given orally as treatment for 






Figure 2-2 (reproduced Table) 
 (Used with Permission, John Wiley and Sons: from Carrera et al., 2018) 
 
Since 2010, the FDA has approved more specialty drugs than standard therapy 
drugs for the treatment of cancer. Specialty drugs are estimated to account for 25% of 
drug spending and constitute one of the largest expenditures for employee health benefit 
plans (Business Group Health, 2018). The costs of these drugs are projected to increase at 
a rate of at least 10% per year, which is probably an unrealistically low estimate 
(Dusetzina et al., 2014). Specialty pharmacies that focus on the distribution of these drugs 
have recently emerged to take advantage of these expensive and lucrative medications, 





The Patient’s Out of Pocket (OOP) Costs 
Cancer treatments have rarely been affordable without insurance coverage, but 
insurance coverage in the past has been robust enough to cover most of the costs of 
traditional, standard treatment (Soni, 2016; Bradley et al., 2016; Shih et al., 2015).  
Specialty medications, however, are usually not covered under the patient’s prescription 
drug benefit.  Coverage of these medications is not like that of intravenous treatments, 
which are often administered in an in-patient or out-patient setting, and as such, are 
covered under most insurer’s medical benefit plans (KFF, 2018).  Now with these new, 
promising treatments being given orally, the cost to patients can be significant with an 
increased share of the cost of treatment shifting to the patient (Schnipper et al., 2016; 
Shih et al., 2015; Morrison, 2015). 
As an example, the tyrosine kinase inhibitor imatinib was introduced in 2001 as a 
first-line treatment for CLL. By 2012, the cost of treatment was approximately 
$92,000/year (Dusetzina et al., 2014).  In 2015, depending on a patient’s insurance 
coverage and the insurer’s policies about specialty medication coverage, the OOP cost of 
imatinib for patients could be nearly $700 per month for 58 months (Shanafelt et al., 
2015). In another estimated calculation about the OOP cost of imatinib in 2014, the 
annualized OOP costs were estimated at $8359 (Kantarjian et al., 2014). Since 2015, 
additional second-generation tyrosine kinase inhibitors have become treatment options 
for CLL. Yet the yearly cost of these second-generation therapies has climbed to more 
than $100,000, accompanied by a higher range of OOP costs to the patient (Dusetzina et 
al., 2014).    
20 
 
Some estimates have these OOP costs as much as ten times higher than OOP costs 
for other medications partially covered on the insurer’s formulary (Hoadley et al., 
2015b). OOP costs can escalate based on whether the price of the medication is based on 
classification as generic or brand drug and whether the medication is on the insurer’s 
formulary as a covered medication (Rotenstein, Dusetzina & Keating, 2018).  Moreover, 
the increase in cost-sharing for more expensive oral specialty drugs has escalated from 
3% in 2004 to an estimated 25% in 2013 (Meisenberg 2015). Further, Davidoff and 
colleagues estimated that 50 % of Medicare beneficiaries with a cancer diagnosis spend 
at least 10% of their income on OOP costs of their cancer treatment (Davidoff et al., 
2013). 
The Medicare Donut Hole 
Most Medicare patients participate in Medicare Part D, a prescription drug 
benefit, which provides coverage for medications through commercial insurance plans. 
Conversely, non-Medicare patients may or may not have a prescription drug benefit 
(Printz, 2014).  Even if medications are covered under a plan, Medicare Part D or 
otherwise, prescription coverage varies widely (Hoadley et al., 2015b). For example, in 
2018, once a Medicare patient enrolled in Part D hits the plan’s initial deductible and 
coverage limits, they become responsible for paying drug costs until they meet the annual 
out-of-pocket threshold. This period when costs are the responsibility of the patient is 
called the coverage gap, also referred to as the “donut hole”. For example, in the case of 
specialty drugs, costs quickly escalate and land a patient in the donut hole. Only after 
21 
 
their OOP expenditures then reach the upper threshold established for the donut hole will 
the insurer resume payment for a percentage of those costs (Medicare, 2018).  
In 2018, the donut hole threshold was $3820.  Due to changes in Medicare 
coverage due to the Bipartisan Budget Act of 2018, provisions related to the donut hole 
will change.  Among factors that affect the cost of drugs to the Medicare Part D 
beneficiary include the beneficiary’s income, whether the medication is brand or generic 
and some additional cost breaks to the beneficiary by the drug manufacturer. 
With the donut hole calculation ending for Part D beneficiaries, the change in how 
medications are charged to the patient is expected to benefit patients required to pay the 
bulk of their prescription costs until they reach the limit of costs established in the hole 
(Medicare, 2018).  With the elimination of the donut hole, it is not yet clear how 
Medicare Part D will cover specialty medications, including oral cancer therapies 
(Cubanski, Rae & Panchal, 2018). It seems likely that patients, Medicare and non-
Medicare, will continue to bear increasing responsibility for the costs of oral cancer 
therapy due to their insurer’s prescription drug benefit limits (Printz, 2014). 
Cancer Treatment and Distress 
Among the many stresses associated with a cancer diagnosis are pain, suffering 
and the fear of death.  For patients who have gone through treatment and are considered 
survivors, they also experience distress that includes fear of recurrence, physical 
challenges from rehabilitation after treatment (i.e., a new normal), financial concerns 
related to continued clinical follow-up and the prospect of more treatment (Massa et al., 
2018; Nipp, Sonet & Guy, 2018). Studies confirm that cancer patients in treatment--or 
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after treatment--report decreased quality of life (QOL) due to factors associated with FT 
(Kale & Carroll, 2016; Delgado-Guay et al., 2015). These patients or cancer survivors are 
at risk or suffer from depression and various anxiety disorders (Kale & Carroll, 2016). To 
establish clarity about the impact that FT has on patients, Gordon and associates 
conducted a systematic review of FT and cancer patients, covering 25 studies published 
from 2013-2016.  From this review, the most common factors associated with FT 
included being female, having a low income, being treated with additional therapies after 
standard treatments and a recent diagnosis (Gordon et al., 2017). 
 
Cancer Care, Financial Toxicity and Distress 
Since patients treated for cancer have been shown to be at higher risk for FT than 
non-cancer patients, FT is of particular clinical concern in cancer care (Soni, 2015). In 
addition to the cost of cancer therapies, the cost of supportive therapies, which reduce 
neutropenic, nausea and vomiting, and anemia can also be high and have increased (Ell et 
al., 2008). 
A cancer patient’s distress, responding to the cost of cancer diagnosis and 
treatment, can be amplified by the additional burden of FT (Kale & Carroll, 2016). For 
patients in distress from FT, this distress can appear as worry, anxiety and/or depression 
(Massa et al., 2018; Chino et al., 2017). Already challenged by the complexities of 
getting through treatment, the stress of paying medical bills is common among these 
patients, with studies estimating that 20-64% of cancer survivors reporting financial 
stress and burden (Guy et al., 2014, Guy et al., 2013: Bernard, Farr & Fang, 2011).  
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A cross-sectional study of 120 insured patients with cancer explored the 
relationship between financial distress, emotional symptoms and overall distress. The 
data, gathered from the InCharge Financial Distress/Financial Well-being Scale and the 
National Comprehensive Cancer Network’s Distress Thermometer, showed that 65% of 
respondents had clinically significant overall distress scores accompanied by at least one 
emotional symptom (i.e., worry, depression, anxiety). The study also reported that due to 
financial concerns, 40% of the sample needed to continue working to pay for treatment 
and medical bills (Meeker et al., 2016). 
Davidoff and colleagues surveyed 1868 Medicare beneficiaries from 1997-2007 
(n = 10,047).    These patients spent a greater proportion of their incomes, often fixed, on 
medical costs compared to those not diagnosed with cancer.  Beneficiaries with cancer 
had statistically significant mean higher OOP costs ($4,727) compared to those without 
cancer ($3,209) (p <.001) (Davidoff et al., 2013). 
In a 2015 review of literature about financial hardship and cancer treatment 
focusing on 13 studies published between 2011-2014, McNulty and Khera determined 
that patients are carrying more of the costs of cancer treatment. Based on their review of 
studies, they identified risk factors associated with FT as patient and family 
sociodemographics, employment and cancer diagnosis-related factors. Consequences of 
FT included patient and family disability status, loss of income, lifestyle changes due to 
reduced income and effect on cancer treatment—including nonadherence or 




Cancer Patients and Financial Toxicity 
Current evidence examining the effect of FT on cancer patients is limited in scope 
and consistency.  Researchers use various methods and measurements and instruments, 
including some unvalidated surveys and questionnaires. Examples include the Health-
Related Quality of Life (HRQOL), the Edmonton Symptom Assessment System (ESAS), 
the Hospital Anxiety and Depression Scale (HADS), the Functional Assessment of 
Cancer Therapy-General (FACT-G), the Comprehensive Score for Financial Toxicity 
(COST instrument), health plan claims, medical record reviews, SEER Medicare data and 
Medical Expenditure Panel Survey Data.  These studies include a wide variety of 
variables, disparate sample populations (advanced cancer patients, cancer survivors, 
specific cancer diagnoses, older cancer patients) and frequently targeted sites limited to 
just one health care system (Wheeler, Spencer & Pinheiro, 2018; deSouza et al., 2017, 
Winn, Keating & Duestzina, 2016; Delgado-Guay et al., 2015; Huntington et al., 2015).  
As a result, comparisons across studies are challenging. Therefore, as Meisenberg stated 
in his 2015 commentary, it is difficult to establish the impact of financial hardship for 
those patients undergoing treatment as well as those who have completed treatment 
(Meisenberg, 2015). Two studies stand out as examples, however. 
First, Yabroff and colleagues analyzed the experience of 1,202 cancer survivors 
with financial hardship, based on survey results from the 2011 Medical Expenditure 
Panel Survey (MEPS) Experiences with Cancer questionnaire.   Respondents reported 
financial hardship due to their cancer diagnosis if they had filed for bankruptcy, had 
problems paying their medical bills, had borrowed money or had to adjust their finances 
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due to cancer treatment.   The analysis showed that younger cancer patient survivors (18-
64 years old) experienced more financial hardship (28.4%) than older cancer survivors (> 
65 years; 13.8%). Those younger survivors, who were uninsured and had lower family 
income, experienced more psychological financial hardship (Yabroff et al., 2016). 
Ekwueme and colleagues studied costs of cancer for survivors.  For the period 
2008–2011, male cancer survivors had mean annual health care expenditures of $8,091, 
compared with $3,904 among males with no cancer history.  Study results for female 
survivors had mean annual medical expenditures of $8,412, compared with $5,119 
among women without a cancer history. (Ekwueme et al., 2014). 
Out-of-Pocket (OOP) Expenses 
OOP expenses are considered any expense or bill that is the responsibility of the 
patient and not covered by health insurance or outside sources of health expense 
coverage.  These OOP expenses can be deductibles and copayments that insurance does 
not cover. They also can be the expense of access to ongoing medical care, which can 
include transportation, hotel, food, medications not covered by insurance (Cabrerra et al., 
2018; Altice et al., 2017; Chino et al., 2017). 
Cancer survivors have reported higher OOP spending on healthcare than non-
cancer survivors. In a review of medical and productivity costs of cancer survivors from 
2008-2011, Ekwueme and colleagues estimate that ongoing medical bills for those 




McNulty and Khera’s 2015 MEDLINE literature review of articles published 
1986-2014 about financial hardship and cancer treatment compiled risk factors and 
consequences of FT to patients and families. Among the risk factors were patient and 
family socio-economic status, employment, logistics to get to and receive treatment and 
the stage and trajectory of disease.   Consequences from FT included decreased 
adherence to treatment, lifestyle changes (avoiding purchases, reduced spending on food 
and staples in the household), borrowing money and bankruptcy (McNulty and Khera, 
2015). 
A 2017 study of 400 breast, colo-rectal, lung and prostate patients in rural 
Australia documented that 21 weeks after their cancer diagnosis, 11% had spent more 
than 10% of their household income on treatment-related costs.  For this sample of 
patients, OOP costs were on average $2,179AU (2018 AUD dollars were 1.39 > US 
dollars) (Newton et al., 2018).  Rotenstein and colleagues conducted a retrospective 
analysis of commercial insurer prescription drug claims for seven years for 13 FDA 
approved oral oncolytics.  The range of monthly OOP costs representing monthly 
prescriptions for 44,113 patients was found to be a range of no cost to as high as $14,157 
with a mean monthly per prescription cost of $82.82.  The mean monthly OOP was 
$2,901 (Rotenstein et al., 2018). Based on data from a 2008–2012 MEPS, Guy and 
colleagues compared 4,271 adult cancer survivors with 96,780 individuals without a 
history of cancer to determine their OOP cost burden. The analysis showed that cancer 
survivors were more likely to report high OOP expenses, especially when they were poor 
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(18.4%).  In addition, cancer patients were more likely to delay medical care (21.6%) or 
delay medical care (19.2%) (Guy et al., 2014). 
Out-of-Pocket Costs as Source of Distress 
A 2018 qualitative study by Ferrell and associates confirmed that from the patient 
and family member perspective, financial distress can be more distressing even than the 
physical, emotional and spiritual distress from cancer and its treatment. The study results 
were based on a convenience sample of 20 family caregivers of cancer patients with solid 
tumors, who were interviewed one time for 20-40 minutes each as part of a larger 
randomized trial about support interventions.  The caregivers described their own 
physical, psychological, social and spiritual wellbeing and financial strain related to the 
patient’s cancer diagnosis and treatment. The researchers reported that caregivers had 
extensive financial concerns; most said they were struggling to pay for care as OOP 
expenses, pay household bills and maintain their credit.  They stated among the costs 
associated with medical care were last minute airplane flights, gasoline, overnight hotel 
stays, restaurant meals and vehicle maintenance.  For caregivers with self-reported 
financial stability with adequate healthcare coverage, they also stated they were anxious 
about their ability to cover future health care expenses (Ferrell et al., 2018). 
Financial Hardship 
In an analysis of 19.6 million cancer survivors from 2011 MEPS data, 28.7% 
reported financial burden due to cancer diagnosis and treatment. Respondents reported 
that 7.6% had borrowed to pay their bills or incurred debt, with 4.2% borrowing less than 
$10,000 and 3% borrowing more than $10,000. Of the respondents, 1.4% had declared 
bankruptcy. Approximately 21% of these cancer survivors were worried about their 
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medical bills, especially as they mushroomed, with 11.5% stating they could not cover 
their medical bills. Based on accompanying physical and mental component scores, those 
with financial challenges had increased depression and worried more about recurrence 
(Kale & Carroll, 2016). 
Using a 2012 LIVESTRONG database of 4,719 cancer survivors, Banegas and 
colleagues determined that approximately one-third of cancer survivors had gone into 
debt, and 3% had filed for bankruptcy.   Of those going into debt, 55% of respondents 
had a debt of $10,000 or more (Banegas et al., 2016). 
Zheng and associates analyzed MEPS data from 2008-2012 to determine the 
economic burden experience by cancer survivors: breast (n = 1568); prostate (n =1170) 
and colorectal (n =540). That burden experience included high medical bills and lost 
productivity (missed work; days in bed). Their analysis indicated that cancer patients 
experience a statistically higher economic burden compared with those without a cancer 
history (Zheng et al., 2016). 
From a pilot study Zafar and colleagues reported about OOP costs and the FT 
experience of 246 cancer patients with solid tumors. They reported that 42% of patients 
receiving chemotherapy or hormonal therapy reported significant financial burden 
associated with their OOP expenses.  For those who did not receive financial assistance 
with the OOP costs of their treatment, their median monthly OOP cost for cancer 
treatment was $708. Not surprisingly, results indicated that FT increased when patients 
were non-white, lower income and had higher psychosocial distress (Zafar et al., 2013).  
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In a study of 2,494 women surveyed from the Carolina Breast Cancer Study 
through the North Carolina Cancer Registry (2008-2013), Black women treated for breast 
cancer experienced worse financial impact when compared to white breast cancer 
patients.  Based on the study’s multivariable logistic regression analysis, black women 
experienced significantly worse financial impact during their cancer treatment. 
Additional factors affecting the experience of FT included loss of job and income and 
challenges with transportation (Wheeler et al., 2018). 
Financial Toxicity and Quality of Life 
Studies have explored relationships among the experience of FT, patient’s 
decreased QOL and patient mortality. Zafar and colleagues have proposed factors that 
may be associated with cancer patients experiencing a perception of high FT that affects 
mortality (Zafar, 2016). These factors include decreased QOL, poorly-perceived 
wellbeing (defined as an “undesirable lifestyle”) and less care due to OOP costs (less care 
associated with non-adherence to prescribed treatments) (Zafar, 2016). Additional studies 
have looked at copay thresholds, when cancer patients may decide not to take prescribed 
medications given orally because they cannot afford the OOP cost of treatment 
(Dusetzina et al., 2013). 
In a cross-sectional study by Delgado-Guay and associates, which evaluated 
overall suffering and QOL in 144 advanced cancer patients treated at a comprehensive 
cancer center and a public hospital in Texas, more than 30% of patients reported that 
financial distress was more than physical distress or distress from family relationships or 
emotional distress. Study data was compiled from validated depression, functional 
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assessment QOL and social support instruments. Moreover, study results reported that 
patients treated at the public hospital had twice the financial distress compared to those 
treated at the cancer center.  
According to this study’s results, distress manifested as depression, anxiety and 
that the patient’s perception of QOL had deteriorated. The authors went on to report that 
for patients with advanced cancer, financial distress is rarely evaluated or reported. 
Delgado-Guay and associates suggest that the impact of financial distress is not yet 
quantified related to other distress-related factors during diagnosis and treatment 
(Delgado-Guay et al., 2015).  
In a 2014 observational, cross-sectional study by Chino and associates of 174 
advanced cancer patient perception of financial burden, 47% reported significant or 
catastrophic financial burden.  The study results suggest that addressing the financial 
burden with cancer patients can affect their general satisfaction with the quality of their 
cancer care and may positively affect adherence to treatment and patient QOL outcomes 
(Chino et al., 2014). 
Financial Toxicity Non-Adherence to Treatment 
A few studies have established a relationship between health care decision- 
making tempered by financial distress. These decisions have resulted in patients taking 
less than their prescribed medications, less monitoring of treatment side effects, less 
attention to signs of recurrence, lifestyle changes that avoid regular primary care visits, 
eating less healthy diets and exercising less regularly. These behavior-based decisions 
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impact whether cancer patients can do well when treated for their malignancies (Wheeler 
et al., 2018; de Souza et al., 2017; Bestvina et al., 2014).   
Desetzina and colleagues reported in a 2014 analysis about patient adherence to 
imatinib, a tyrosine kinase inhibitor, used as a treatment for patients with CML. They 
reported 2002 thru 2011 data from large employers, health plans and government insurers 
for 1,541 patients with initial insurance coverage for the treatment.  The monthly 
copayment for the medication averaged $108 with a range of copayments $0 to $4,792.  
The study data suggests that when OOP costs of the treatment were higher, patients had 
lower adherence to the treatment, estimating 42% of patients were more likely to be 
nonadherent to the treatment with higher copays. Therefore, patients with higher 
copayments were more likely to be nonadherent or discontinue treatment.  Moreover, 
70% of the respondents were most likely to stop taking the therapy within six months of 
starting therapy when the monthly co-pay was more than $53 (Desetzina et al., 2014).   
From a cross-sectional survey of 164 patients participating in a copay assistance 
program and treated for solid tumor malignancies 2019-2011, Zullig and colleagues 
reported that 45% of the patients reported not adhering to prescribed prescriptions due to 
the cost of treatment.  This non-adherence included not filling their prescriptions, taking 
less than the prescribed treatment or taking medication that was prescribed for others. 
The results also indicated that those who were non-adherent to the prescribed treatment 
spent less of their household income on food and clothing and were more likely to use 
credit cards to pay for medication (Zullig, Peppercorn & Schrag, 2016).  
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Winn and associates evaluated the affordability of anti-cancer therapies (tyrosine 
kinase inhibitor) given orally for CML.  Using the SEER-Medicare database from 2007-
2011 of 393 patients, only 68% started therapy within three months of diagnosis.  The 
researchers suggested that the OOP costs may prevent patients from starting therapy as 
prescribed. From the study, factors contributing to nonadherence to treatment decreased 
with age, especially for patient 80 years or older (Winn et al., 2016). 
Finally, in a 2014 cross-sectional survey study at Duke Cancer Institute, 300 
patients during 2012-2013 were asked if they had discussed with their oncologists the 
OOP costs for their cancer treatment given orally.  Only 19% of them reported they had 
discussed costs with their oncologist.  As to OOP cost of the therapy affecting whether 
they followed the medication instructions as prescribed, 27% stated they did not follow 
through taking the medication as prescribed, 14% stated they missed medication doses 
and 11% stated they took less than the medication prescribed—all due to the cost of the 
medication (Bestvina et al., 2014). 
Gap Analysis 
This study attempts to fill a gap in what is known about the experience of FT for 
patients treated for cancer with therapies given orally and the relationship of that 
experience with the patient’s perception of distress and adherence to the prescribed 
treatment. Few studies have focused on FT experienced by cancer patients. In September 
2017, a search of the PubMed database of studies from the past ten years resulted in few 
studies about FT and cancer (44), financial hardship and cancer (61) and financial distress 
and cancer (44). This accounting of studies compared with a PubMed search not linked to 
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the word “cancer” of FT (55), financial hardship (433) and financial distress (152) 
(Carrera et al., 2018). 
A 2016 systematic review of the previous six years of peer-reviewed studies 
looked at the cost of illness and its effect on cancer patients.  The review confirms that 
FT studies lack consistency of rigor in their design and methods (Gordon et al., 2017). 
Gordon’s review identified 25 relevant studies, with only 15 from the United States.  
Eighteen studies were cross-sectional; the remainder of studies were prospective or 
retrospective cohort studies. The study measures varied with some reporting FT as a 
subjective measure, with 15-73% of respondents reported experiencing FT. Objective 
measures of FT included non-adherence to treatment, delays in starting treatment, not 
proceeding with treatment and changes in insurance coverage affecting the patient’s 
experience of FT. This systematic review confirms there are precious few rigorous 
studies about FT with cancer patients and any comparison of data or conclusion across 
studies is problematic (Gordon et al., 2017).  
To date, studies of FT in cancer patient populations have adopted various study 
designs, procedural methods and data analysis.  In general, studies have had small sample 
sizes or have performed secondary data analysis, extracting data about patients’ financial 
toxicity experience based on broad interpretations (Gupta et al., 2018; Huntington et al., 
2015; Pelletier & Bona, 2015; Delgado-Guay et al., 2015).  
The literature review for this study confirms that measuring FT in cancer patients 
is a new focus of clinical care. Only one measurement instrument, the Comprehensive 
Score for Financial Toxicity (COST), has a published evaluation of its reliability and 
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validity (deSouza et al., 2014). Otherwise, the assessment of FT in cancer patients is 
based on a broad list of instruments.  Without a focus on FT, many instruments are not 
established as reliable, without published psychometric evaluations related to FT and 
specific populations (Gupta et al., 2018; Pelletier & Bona, 2015; Delgado-Guay et al., 
2015;  Chino et al., 2014; Bestvina et al., 2014). In some studies, there has been a focus 
on evaluating clinical depression or anxiety as equivalent to the experience of FT and 
distress (Kale & Carroll, 2016; Meeker et al., 2016). Data has also been gathered from 
surveys, the medical record or large insurance claim or cancer-registry data bases 
(Yabroff et al., 2016; Chino et al., 2014; Guy et al., 2014; Guy et al., 2013; Wheeler et 
al., 2013). 
Several thought leaders in the emerging field of FT have weighed in with 
insightful commentaries about the need to further study FT and its relationship with the 
patient’s psychosocial status and adherence to treatment (Meisenberg, 2015; Zafar, 2015; 
Kantarjain et al., 2014; Light & Kantarjian, 2013; Ubel, Aberneth & Zafar, 2013). But 
those commentaries refer to few published studies based on clinical data, with their 
commentaries urging the need for further research. They state that a foundation to build 
effective interventions to address FT requires clinical attention and study. Data-based 
studies form the foundation for clinical care, which can lead to more open discussions 
between patients and their providers about the value of treatments within a care plan. 
Studies also can serve as a foundation for more effective decision-making and guidelines 
for standards of care (Santacroce, Tan & Killea, 2016; Delgado-Guay et al., 2015). 
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Moreover to date, FT studies do not focus on cancer patient populations with any 
specificity or acknowledgment of complexity. These studies are limited in their insights 
about cancer patients with a particular diagnosis, stage of their cancer, choice of novel 
treatments, time or duration of their treatment or survivorship status (Wheeler, et al., 
2018; McNulty & Khera, 2015).   Analysis of health care expenditures associated with 
insurance carriers provide some understanding of the financial burden of care. But little is 
known about FT when insurance coverage changes, when those changes affect the 
patient’s OOP costs and financial burden (Gupta et al., 2018; Fessele, 2017; Fenn et al., 
2014). 
Summary of Literature 
This review of the literature related to FT in cancer patients confirms a challenge 
to patients undergoing treatment that is becoming more concerning.  Moreover, the high 
costs of cancer therapies given orally have become more the responsibility of the patient 
(KFF, 2018; Guy et al., 2015; Hoadley, 2015a).   These OOP costs are the source of 
distress to patients, as evident by patients’ reports of more worry, depression and anxiety 
(Massa et al., 2018; Chino et al., 2017; Delgado-Guay et al., 2015).  
Studies about FT associated with cancer treatment have focused on financial 
burden of treatment (Guy et al., 2013; Guy et al., 2014; Bernard et al., 2011).  To define 
the components and impact of FT, studies have used a variety of study designs, 
measurement strategies and instruments (Gupta et al., 2018; Huntington et al., 2015).  
Some FT measurement instruments have been evaluated for reliability and validity of 
findings (deSouza et al., 2017).  The majority of studies have not used reliable 
36 
 
measurement instruments that can produce reliable, valid data (Gupta et al., 2018, 
Pelletier & Bona, 2015; Delgado-Guay et al., 2015. Chino et al., 2014; Bestvina et al., 
2014).). 
The first documented reliable FT instrument to produce valid data is the COST. 
Since it is the first FT instrument tested as reliable, use of the COST instrument is a 
method to establish standard FT measurement across different studies (deSouza et al., 
2017).  
Gaps in what is known about the relationship of FT to the experience of patients 
treated for cancer include the nuances of financial distress and adherence to treatment, 
decision-making and patient preferences about their plan of care (Santacroce et al., 2016; 
Delgado-Guay et al., 2015). Those who have studied FT recommend establishing 
coherence in the approach to FT, understanding the context in which FT occurs and 
conducting more studies with robust designs using reliable measurements and 
instruments (Carrerra et al., 2018; Altice et al., 2017).   Yet no studies to date have 
studied cancer patients receiving therapies given orally and the relationships to their 
adherence to prescribed treatment, their experience with FT and their perception of 
distress.   
To better inform health care professional discussions with patients about 
treatment and their impact on patients and their family members, this study intends to 
better describe the participant experience of FT and its relationship with patient distress 






This chapter includes a discussion of the study design; a description of the 
population, study procedures for participant recruitment and data collection, and the plan 
for data management and statistical analysis.  
Purpose and Specific Aims 
The purpose of this study was to describe the relationships between the patient 
experience of financial toxicity (FT), patient perception about distress and patient 
adherence to prescribed therapy in a sample of cancer patients treated with therapy given 
orally. 
Study Design 
This study used a descriptive cross-sectional correlational design to describe the 
relationships between the patient experience of FT, patient perception about distress and 
patient adherence to prescribed treatment in a sample of cancer patients treated with 
therapy given orally.   
Sample  
The sample of participants had received or are receiving treatment for 
hematologic and solid tumor malignancies given orally. 
The inclusion criteria for participants were adult patients (21 years or older) who 
are Spanish or English speaking, have the ability to read English and have an initial 
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diagnosis of these malignancies:  Breast cancer, head and neck cancer, Hodgkin’s 
Lymphoma, lung cancer, leukemia, lymphoma, melanoma, multiple myeloma, 
myeloproliferative neoplasms, pancreatic cancer and prostate cancer. Participants’ 
oncologists had prescribed a cancer treatment regimen for at least four weeks and given 
orally. The participants’ health insurance coverage included private health insurance or 
coverage by Medicare (Medicare Fee for Service (FFS), Medigap or Medicare Part C 
(Advantage). 
The exclusion criteria for study participants included patients who had not been 
prescribed cancer treatment given orally (i.e. infusion only, radiation and/or surgery only) 
and those receiving in-patient cancer treatment. In addition, excluded study participants 
were those covered by Medicaid or those without health insurance coverage. 
Setting  
The patient education/advocacy organization Patient Power® was the setting for 
the study. Patient Power® provides education, information, resources and support to 
patients diagnosed with cancer, their family members and caregivers.    
Patient Power® is a service of Patient Power®, LLC, based in Carlsbad, CA with 
members participating from around the world (Patient Power, 2018).   In 2005, two 
health communications pioneers, Andrew and Esther Schorr, founded Patient Power®.   
The Schorrs have extensive professional and career experience in healthcare 
communications.  Moreover, their commitment to Patient Power® is based on their own 
experience with cancer:  Andrew is a two-time cancer survivor (chronic lymphocytic 
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leukemia (CLL); myelofibrosis (MF).  He was first diagnosed in 1996. Esther has been 
his care partner over 20+ years.  
The foundation for Patient Power®’s communication and exchange is its open-
access web site:  www.patientpower.info. As of September 2018, Patient Power had 
approximately 23,000 contactable community members.  For a participant to become a 
contactable community member (registered, receiving a free subscription to Patient 
Power’s information and resources), the participant is required to register (establish a 
password and submit the participant’s e-mail address to Patient Power®).  With 
membership, the participant receives e-Alerts and invitations to online and in-person 
events.) Tables 3-1 shows the demographics of the Patient Power®  membership.  Table 
3-2 provides a breakdown of its membership.   
In 2018, the Patient Power® site had approximately 70,000 visits to the site per 
month.  Patient Power® also builds traffic to its site from its Facebook community page 
(35,000 visits/week) and from additional website platforms: LinkedIn, Twitter, and other 
social media channels.   
Patient Power®  follows HIPAA privacy guidelines to protect membership data.  
It complies with the HONcode Standard for trustworthy health information.  It is in 
partnership with major medical institutions and advocacy groups to continually ensure 
the veracity of its information and resources.   Among its collaborative partners for 
education and advocacy are the Leukemia and Lymphoma Society, CLL Research 






Patient Power® Community Demographics (2016) 





Patient Power® Member/Subscriptions (2018) 





This study’s target sample size was based on an a priori analysis from three 
previous studies about FT as a clinical factor in patient care (Gupta et al., 2018; 
Shankaran et al., 2018; Huntington et al., 2015).  Samples from those studies included 
sample sizes of 118, 34 and 100 patients.  In addition to supporting a target sample size, a 
power analysis was calculated using G*Power version 3.1.9.2. The G*Power calculation 
used a medium effect size of 0.15, based on a one-way independent analysis of variance 
(ANOVA) at 0.95 power, eight anticipated predictors and significance of 0.05.  The 
G*Power calculation resulted in 89 participants.  Therefore, taking into account previous 
study samples, the G*Power calculation and anticipated incomplete, missed and outlier 
data, this study’s sample size was targeted at a minimum of 120 participants for 
responses to contribute to the data analysis. 
Protection of Human Subjects 
The study was reviewed by the Institutional Review Board of the University of 
San Diego. (Appendix A.)  This review confirmed that study participants were recruited 
according to the National Institute of Health (NIH) guidelines Protecting Human 
Research Subjects (NIH, 2018).  The study design did not present inherent adverse 





Recruitment of Participants 
The study investigator recruited a convenience sample of participants by 
accessing participants (patients only) from the Patient Power® community.  With 
permission from the Patient Power® site administrator, the study investigator posted 
information about the study (including the inclusion/exclusion criteria) on the Patient 
Power® website. (Study Blurb: Appendix B.)  If potential participants were interested in 
reviewing more information about the study or proceeding to sign up as a study 
participant, the study instructions guided interested members from the Patient Power® 
community to proceed via link to Website #1, managed by the investigator, with more 
information about the study and procedures provided about joining the study (Appendix 
C, Web site #1 content.). 
On Website # 1, the Study Investigator provided potential interested participants 
with a study synopsis, FAQs about the study and the Study Investigator’s contact 
information if potential participants had questions or need further clarification about the 
study. Website #1 also included instructions to sign up for the study, which included 
instructions to complete the informed consent and the informed consent itself.  
If after reviewing the study information on WebSite #1, the participant did not 






When a participant responded that he/she wanted to sign up for the study (signed 
informed consent posted), the Study Investigator contacted the participant via e-mail with 
instructions to proceed to a participant password-protected site to complete the three 
study instruments (Appendix D. Web site #2). Web site #2 (Advantage Survey Monkey 
platform) included the study synopsis (again), contact information about the Study 
Investigator and instructions to proceed to complete surveys listed in Appendix E, F and 
G.  Participant’s responses were automatically entered into a .cvs file within Advantage 
Survey Monkey®  and only accessible to the investigator.  
At all times, participation in the study remained voluntary.  Participants could 
choose to answer only those questions they chose to answer.    
Data Management 
To secure the data and ensure confidentiality, participants and their survey 
responses were deidentified.  The study investigator accessed participant data and survey 
results from a password protected file, provided by the Advantage Survey Monkey® 
platform (https://www.surveymonkey.com). The .cvs file was uploaded to the 
investigator’s computer. Files of the dataset were stored in a secured environment 
(lockable computer system with passwords). 
To prepare the data for analysis, the Study Investigator reviewed and cleaned the 
data, accounting for missing, invalid or outlier data.  The data was coded to assess for 
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Operational Definitions of Terms 
As a review, here are operational definitions pertinent to this study: 
Financial Toxicity (FT):  In cancer care, the objective and subjective financial 
consequences of cancer treatment, which may include significant OOP costs, loss of 
income, and caregiver burden. Since 2011, the term financial toxicity also has been 
associated with patients diagnosed with cancer who face significant financial challenges 
related to precision medicine as a foundation for treatment (Carrera, 2017; Zhang, 
Hueser, & Hernandez, 2017). 
Cancer Treatments given Orally: Molecular and genetically-based cancer treatments that 
are prescribed in oral form (i.e. not intravenous or intraperitoneal infusions) (Carrera, 
2017; Zhang et al., 2017). 
Perception of Distress:  Perception of Distress is an unpleasant emotional state 
experienced by an individual, which may affect feelings, thoughts, and actions. It can 
include feelings of unease, sadness, worry, anger, helplessness, and guilt (NCCN, 2018). 
Adherence to Treatment: Taking a prescribed medication or treatment exactly as 
prescribed, including dose or rate, schedule and formulation (Bestvina et al., 2014; Zullig 




Demographic Questionnaire.  The first instrument was the Demographics 
screen.  It included standard demographic questions, including cancer diagnosis, gender, 
age, gross household income, level of education, employment status and insurance 
coverage, as well as questions about the participant’s cancer therapy given orally. 
(Appendix E). 
The study used two validated study instruments: 
Comprehensive Score for Financial Toxicity (COST). The COST is a 
measurement instrument to assess a respondent’s experience with FT (Appendix F.).  It is 
an 11-item instrument that covers one financial question, two resource item questions and 
eight affect-focused questions about the respondent’s experience with FT. Lower COST 
scores indicate higher levels of FT (DeSousa et al., 2017; DeSouza et al., 2014). 
The COST measure demonstrates high internal consistency and test-retest 
reliability.  Specifically, COST scores have been shown to correlate with income 
(correlation coefficient r = 0.28; p<.001), psychosocial distress (r = 0.26; p<.001), and in 
comparison to the Health-Related Quality of Life (HRQOL) instrument, as measured by 
the FACT-G (r = 0.42; p<.001) and by the EORTC QOL instruments (r = 0.33; p<.001) 
(DeSousa et al., 2017; DeSouza et al., 2014).  The COST instrument has a Cronbach 
alpha value of > .90., confirming reliability and that it generates valid data (DeSousa et 
al., 2017; DeSouza et al., 2014). 
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The COST instrument is relatively new to research practice with a few studies 
reporting results when used (Huntington et al., 2015). In a 2013 study by Zafar and 
associates in two Chicago-area hospitals, the COST measure demonstrated high internal 
consistency and test-retest reliability when evaluating FT (Zafar to al., 2013c).   Although 
considered a reliable instrument to evaluate FT in cancer patients, the COST is not yet 
widely used (Huntington et al., 2015).  
National Comprehensive Cancer Network (NCCN) Distress Thermometer 
(DT).  The National Comprehensive Cancer Network (NCCN) Distress Thermometer and 
accompanying Problem List (DT) (Appendix G)  has been widely used internationally 
and in a variety of clinical cancer patient care settings (NCCN, 2018; Baken & Wooley, 
2011).  The DT consists of a 1-10 scale (0 = no distress; 10 = extreme distress), 
identifying any source of distress to the patient.  Scores of 4 or higher on the DT suggest 
clinically significant distress (Ploos van Amstel et al., 2017).  
The DT has been shown to effectively assess distress in cancer patients (Mitchell, 
2007; Donovan et al., 2014).  Its reliability and validity as a measurement instrument has 
been demonstrated in 38 pooled studies, representing 14,000 patients with cancer.  The 
pooled sensitivity of the DT has been established at 81% (95% CI, 0.79-0.82) at a cutoff 
score of 4 (Ma et al., 2014). The DT has a specificity of α = 0.70 for detecting clinical 
levels of distress (Jacobsen et al., 2005).  
When a patient’s score is 4 or greater, the provider can further target the patient’s 
distress by assessing the patient’s response to the instrument’s 39-item accompanying 
Problem List. From the Problem List, items are categorized in 5 areas: practical, family, 
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emotional, spiritual/religious and physical (NCCN, 2018). Under the Practical Problems 
category, Insurance/Financial is an option that the patient can choose to mark: yes or no. 
When the patient marks yes, the provider can follow-up on that problem area with 
education, support and resources (NCCN, 2018).  Two studies have validated the DT 
instrument with the expanded Problem List, which includes Insurance/Financial as a 
Problem (positive predictive value: 39%: negative predictive value: 95%.) (Graves et al., 
2007; Tuinman et al., 2008).  
Data Analysis 
All data analysis was performed using IBM SPSS Statistics, version 26.  
The study’s three aims and the statistical analysis plan for each aim follows: 
Aim #1. To describe sociodemographic, clinical and financial characteristics, the 
experience of FT, perception of the level of distress, and adherence to treatment in a 
sample of adult participants who have received or are receiving treatment given orally for 
hematologic or solid tumor malignancies. 
To meet this aim, descriptive statistics were computed for all study variables to 
determine the overall characteristics of the sample and the distribution of variables.  
Aim #2. To describe relationships between participant sociodemographic, clinical and 
financial characteristics, participants’ experience of FT, participants’ perception of 
distress, and participants’ adherence to treatment.    
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To meet this aim, the study analysis examined relationships between the 
covariates of participant sociodemographic, clinical and financial characteristics, 
participants’ experience of FT, participants’ perception of distress, and participants’ 
adherence to treatment. Variables underwent bivariate analysis and modeling. Analysis 
was expected to control for the demographic characteristic. Variables were entered in the 
logistic regression model and examined for linearity, multicollinearity and outliers. 
To establish potential associations between the study’s variables (categorical), 
Pearson’s Coefficient Correlation analysis was performed.  Then nonparametric analysis 
(Spearman’s Rank Order Correlation) was performed on selected variables to determine 
if any study variables had significant correlation not established with parametric analysis. 
Aim #3. To explore the likelihood that participant experience of FT predicts participant 
perception of distress and non-adherence to the treatment given orally.  
From the bivariate analysis completed for Aim #2, variables significant at p < 0.5 
were to be entered in logistic regression models to determine the likelihood that 
participant experience of FT predicts participant perception of distress and/or non-
adherence to the treatment given orally.   
Strengths and Limitations of Methods 
By using an on-line patient education/advocacy site to recruit study participants, 
the participants were self-selected as a) cancer patients, b) cancer patients treated with 
cancer treatments given orally, and c) cancer patients who were motivated to know and 
learn about their cancer, its treatment and the operational issues related to their treatment. 
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Participants recruited from the advocacy site, Patient Power®, were not 
representative of cancer patients, any standardization of insurance coverage for patients 







This chapter presents the results of the study, including a narrative description, 
supported by 25 tables supporting the data analysis. (Tables follow this chapter.)   The 
analysis described the data, using descriptive statistics.  Further analysis addressed each 
of the study’s aims, establishing relationships among the study variables and whether the 
total COST instrument data (representing financial toxicity (FT) could predict patient 
distress or adherence to treatment. 
The Study 
This study employed a descriptive, cross-sectional design using convenience 
sampling and validated survey instruments.  The study described characteristics about the 
sample, relationships among the sample’s variables related to the experience of FT, 
perception of distress and adherence to prescribed cancer treatment given orally. 
Data Collection 
 The study’s data were collected on-line from 136 participants, who were members 
of the patient education/advocacy community, Patient Power®.  Participants in the study 
were self-identified as diagnosed with a malignancy and prescribed a cancer treatment 
given orally.  Participants completed three study instruments—the 27-question 
Demographic Questionnaire, the 11-item, Likert-scale Comprehensive Score for 
Financial Toxicity (COST) and the 0-10 scaled National Comprehensive Cancer Network 
(NCCN) Distress Thermometer (DT).    The study period was six weeks, March 1 to 
April 15, 2019.  
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The study investigator accessed the participant data and survey results from a 
password protected file, provided by the Advantage Survey Monkey® platform. All data 
files were uploaded to the investigator’s computer and stored in a secured environment 
(lockable computer system with passwords). 
To prepare the data for analysis, the Study Investigator reviewed and cleaned the 
data, accounting for missing, invalid or outlier data from all three study instruments. 
Pairwise deletion was the method used to account for any missing data during data 
analysis.   Continuous data were evaluated through parametric testing; linearity was 
established via scatter plot evaluation.  
The data was transferred to SPSS v26 Statistical Package for data analysis. 
Study Aim #1 
Aim #1 
Based on the sample data, to describe sociodemographic, clinical and financial 
characteristics, the experience of FT, perception of the level of distress, and adherence to 
treatment in a sample of adult participants who have received or are receiving treatment 
given orally for hematologic or solid tumor malignancies. 
Aim #1: Analysis 
To address Aim #1, descriptive statistics, specifically frequencies and 
percentages, were calculated to provide a summary of the characteristics of the sample 





The study sample included 136 participants, who completed or partially 
completed the study’s three on-line surveys. Tables 1a, 1b, 1c compile demographic 
characteristics about the study’s participants.  Participants completed the three surveys at 
one time.  For some of the questions related to the COST instrument (FT) and the 
Distress Thermometer (DT), participants were asked about their perceptions at two time 
points: 1) Perceptions at one-week post start of treatment prescribed orally, and 2) 
Perceptions at six months post start of treatment prescribed orally.  
More women (n =75, 51.1%) than men (n = 61, 44.9%) participated in the study.  
More than two thirds of the participants were > 65 years old (n = 93, 68.4%)—an age 
threshold expected since the study focused on participants diagnosed with malignancies 
more prevalent with age.  In addition, many of the treatments for the cancer diagnoses 
represented in the study sample are treatments given orally.  
The majority of participants were married or had a domestic partner (n = 112, 
82.4%).  Participants’ educational backgrounds skewed to well-educated with almost one 
third completing some college credits (n = 48, 35.3%). Approximately two thirds of study 
participants had earned graduate credit and/or graduate degrees (n = 88, 64.7%). 
Due to the age of the study participants, most participants at the time of the study 
period were not employed (n = 93, 74.4%).  However, 54% of the study participants 
reported they were employed when they started their cancer treatment given orally (n = 
67, 54%). Of the study participants, two thirds reported that their cancer treatment did not 





The most common diagnoses of the study participants were chronic lymphocytic 
leukemia (CLL) (n = 54, 41.5%) and multiple myeloma (MM) (n = 34, 26.1%), 
accounting for more than two thirds of the survey participants’ diagnoses.   The 
treatments that participants were prescribed in oral formulation were in keeping with the 
recommended or standard-of-care treatments for their cancer diagnoses. The most 
frequently cited therapies reported by the participants were imbrutinib (Imbruvica®), 
lenalidomide (Revlimid®) and ruxolitinib (Jakafi®).   Most of participants (n = 118, 
86.7%) reported that despite challenges to stay on their treatments given orally, they 
maintained their treatment dosing schedules.    
Only 2.9% (n = 4) of study participants reported that they had skipped taking their 
cancer treatments given orally due to the cost of treatment. Few study participants 
reported that they had stopped taking their non-cancer medications (n = 5, 3.8%) or took 
some of their non-cancer medications (n = 5, 4.0%) or adjusted the dose of their non-
cancer medication (n = 8, 6.5%) due to the cost of their cancer treatment (Table 4-1b).  
Financial Characteristics 
Almost three fourths of study participants responded that they financially 
supported themselves and a partner (n = 92, 75.5%).  Another quarter of the participants 
responded that they were single, financially supporting only themselves (n = 28, 24.0%.)  
Of those responding to the question about gross income, 70% of participants had a gross 
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income <$100,000/year (n = 82, 70.0%) with the remaining participants reporting a gross 
income of >$100,000/year (n = 35, 29.8%) (Table 4-1c). 
Covering the Cost of Cancer Treatment Given Orally 
The majority of the sample participants were covered by health insurance (n = 
128, 98.4%), which fully or partially covered their cancer treatments given orally. Health 
insurance coverage represented in the sample included Medicare alone (n = 32, 27%), 
Medicare with Medigap coverage (n = 33, 27.5%), Medicare Advantage (a managed care 
coverage option for Medicare) (n = 7, 6%), and private insurance (n = 46, 39.0%).  Most 
participants had prescription drug coverage, either Medicare Part D (n = 65, 56.0%) or 
private insurance drug coverage (n = 47, 40.5%) (Table 4-1b) 
For study participants receiving financial support from pharmaceutical, 
foundation or other non-insurance sources to cover their treatment cancer costs, they 
were generally split between those who received support (n = 57, 46.3%) and did not 
receive support (68, 54.0%).   Of note, approximately half of study participants did not 
respond to the question about the percentage of financial support received from non-
insurance sources.  For study participants who did respond about receiving non-insurance 
support for their treatment (n = 66, 52.8%), 27.2% (n = 34) received 50-100% support; 
7.2% (n = 9) received 20-50% support and 10.4% (n = 13) received < 20% support 
(Table 4-1b). 
After cancer treatments given orally were covered by insurance or non-insurance 
sources, 91% of study participants reported that they were responsible for < 20% of the 
cost (n = 52, 43%); 20-50% of the cost (n = 22, 18%) and 5-100% (n = 6, 5%).  The 
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remaining participants (n =30, 16.5%) reported they were partially responsible for the 
cost of their treatment, based on copays and various OOP cost calculations. (Table 4-1b) 
Participant Experience of Financial Toxicity 
The COST instrument scores, which indicated participants’ perception of their FT 
experience at one week and six months after the start of treatment, were analyzed as 
percentages, frequencies, means and standard deviations (SDs) (Tables 4-2a, 4-2b). 
Comparing the total COST scores (n = 119) at the two time points, the means and 
range of scores were similar: at seven days post start of treatment (M = 25.13, SD = 
5.154, range: 10-39); at six months post start of treatment (M = 25.17, SD = 5.614; range 
8-39).  (NOTE: Overall range of COST scores: 0-44; COST score cutoff for high FT = 
≤24; for low FT = > 24.)   
For the eleven individual COST items scored on a 5-point Likert scale, Table 4-2a 
and 4-2b provide frequencies and percentages of responses.  For participant perceptions 
at one week after cancer treatment began, COST items that prompted quite a bit or very 
much concern were “feel no choice about cost of care” (n = 89, 75.4%), “worry about 
future financial problems due to illness” (n = 70, 72.2%), “higher than anticipated out of 
pocket medical expenses” (n = 74, 67.1%), “reduced satisfaction in current financial 
situation due to cancer treatment” (n = 69, 58.5%),  “ability to meet monthly expenses”  
(n = 60, 52.1%) and “overall financial stress” (n = 53, 45.7% (Table 4-2a).  
For participant perceptions at six months after beginning their cancer treatment 
given orally, items that prompted quite a bit or very much concern were “feel no choice 
about cost of care” (n = 92, 80.0%), “worry about future financial problems due to 
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illness” (n = 80, 68.9%), “higher than anticipated out-of-pocket medical expenses” (n = 
69, 59.4%), “reduced satisfaction in current financial situation due to cancer treatment” 
(n = 63, 56.7%), “ability to meet monthly expenses” (n = 59, 50%) and “overall financial 
stress” (n = 58, 49.5%) (Table 4-2b). 
Out-of-Pocket Expenses 
Of 115 study participants responding to the Demographics instrument questions 
about monthly out-of-pocket (OOP) expenses associated with cancer treatment given 
orally, 66% (n = 78) estimated < $500/month OOP expenses and 34% (n = 40) estimated 
> $500/month OOP expenses.  
Study participants responded to the types of OOP expenses on both the 
Demographics and COST instruments (Tables 4-3, 4-4). From participant responses to 
the Demographics instrument question, participants’ OOP expenses included 
transportation (gas and parking) (n = 101, 86.3%), over-the-counter medications (n = 67, 
57.2%), hotel costs (n = 35, 29.9%), lost wages (n = 23, 19.7%), miscellaneous costs (pet 
care, prescription medications, medical marijuana, meals and flights traveling to 
appointments, chiropractic/massage) (n = 6, 6.0%) and child care (n = 3 2.6%) (Table 4-
3). 
Financial Toxicity and Perception of Distress 
Perceptions of high distress due to FT at one week post start of treatment given 
orally were 42% (n = 39) and 39% (n = 38) at six months post start of cancer treatment 
given orally.  Of note, 32% of study participants (n = 44) did not respond to the one week 
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after treatment start question. For perception of distress at six months after start of cancer 
treatment given orally, 29% of study participants (n = 38) did not respond. (Table 4-4) 
From the DT instrument questions about sources of cancer diagnosis-associated 
distress (categorized as practical, family, emotional, physical and spiritual problems), 
55.7% (n = 64) of the participants cited insurance and financial problems as a source of 
distress (Table 4-5.).   
 
Financial Toxicity (FT) and Adherence to Treatment 
From study participants responding to the question about adherence to cancer 
treatment given orally (n = 136), only 8% of participants (n = 11) reported that they 
stopped, interrupted or altered their prescribed cancer treatment given orally (Table 2.). 
 
Study Aim #2 
 
Aim #2 
From the study data, describe relationships between sociodemographic and 
clinical characteristics and 
1) the participants’ experience of FT (Sub Aim #1) 
2) the participants’ perception of distress (Sub Aim #2) 
and 




Aim #2:  Analysis 
The Pearson’s Correlation Coefficient was calculated to evaluate bivariate 
correlation between total COST scores at the two time points and the DT scores at the 
two time points. (Tables 4-6).  The Pearson’s Correlation Coefficient was also calculated 
to evaluate any bivariate correlation relationships between COST scores at the two time 
points and selected demographic, clinical and financial characteristics—including 
adherence to treatment (Tables 4-7 through 4-25). Pairwise comparisons were calculated 
for selected demographic variables, for clinical variables and for financial variables 
(Tables 4-14, 4-15, 4-16).  
 
Relationships between Financial Toxicity and demographic, clinical and financial 
variables  
For Aim #2, Sub-Aim 1--to describe relationships between sociodemographic and 
clinical characteristics and the participants’ experience of FT--based on Pearson’s 
Correlation Coefficient analysis, weak statistically significant relationships were found, 
comparing total COST scores at one week and six months after start of cancer treatment 
given orally for these variables:  
At seven days post start of treatment, COST scores to had a drug plan (r = -.185, p 
= .035) (Table 4-9); to affected employment (r= .282, p = .002) (Table- 4-11); and 
adherence (r = -.260, p = .003  (Table 4-13).   NOTE:  Using non-parametric analysis 
(Spearman’s Rank Order Correlation), there also was weak correlation, COST Scores at 
seven days post start of treatment to OOP costs (rs = .259; p = .005) (Table 4-11).  
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At six months post start of treatment, COST scores to had a drug plan (r = -.201, p 
= .022) (Table 4-10); to affected employment (r = .326, p < .001) (Table 4-12); and to 
adherence (r = .245, p = .005) (Table 4-13). NOTE:  Using non-parametric analysis 
(Spearman’s Rank Order Correlation), there also was weak correlation, COST Scores at 
six months post treatment to OOP costs (rs = .340, p <.001) (Table 4-12)  
For demographic variables, correlation coefficients were established between 
gender and age (r = .301, p < .001); gender and living status (r = .224, p. = .009); and 
education to living status (r= -.264, p = .002) (Table 4-14). 
For clinical variables, a moderate correlation coefficient was established between 
skipping cancer treatment and taking some of the prescribed non-cancer medications (r = 
.600, p = < .001). Weak correlation coefficients were established between lowering the 
prescription of non-cancer medications and taking some of the prescribed non-cancer 
medications (r = .386, p = <.001); and being covered by insurance and being covered by a 
drug plan (r = .219, p = .013) (Table 4-15).  In addition, adherence was correlated to 
having a drug plan (r = .345, p = <.001) (Table 4-24). 
For financial variables, weak correlation coefficients were established between 
employed now and employed when started treatment (r = .393, p = < .001); treatment 
affected employment and income support (r -= .238, p = .009); income support and gross 
income (r = .283, p = .002); gross income and receiving help from pharmaceutical 
companies/foundations (r =.354, p = <.001); gross income and percentage of help 
received from pharmaceutical companies/foundations (r = .336, p = .001); received help 
from pharmaceutical companies/foundations and OOP monthly costs (r = .351, p = .001); 
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and percentage help from pharmaceutical companies/foundations and OOP monthly costs 
(r = .274, p= .003). (Table 4-16). In addition, adherence was weakly correlated to income 
support (r = -.055, p = >.001) and gross income (r = .188, p = .045) (Table 4-25).   
A strong correlation coefficient was established for received help from 
pharmaceutical companies/foundations and percentage financial help from those non-
insurance sources (r = .869, p = .001) (Table-4-16) 
For perception of distress and demographic, clinical and financial variables, the 
only statistically significant, albeit weak relationship was perception of distress at six 
months post start of treatment and the percentage of help from pharmaceutical/foundation 
sources (r = .336, p = .001) (Table 4-22). 
 
Relationships between Financial Toxicity and Perception of Distress  
For Aim #2, Sub-Aim 2--to describe relationships between the participants’ 
experience of FT at the two time points and participants’ perception of distress (DT)—
there was no statistically significant relationship calculated in the sample, based on 
Pearson’s Correlation Coefficient calculations. 
 
Relationships between Financial Toxicity and Adherence to Treatment 
For Aim #2, Sub-Aim 3--to describe the correlation between the participants’ 
experience of FT and the participants’ adherence to treatment, there was a weak negative 
correlation at both time points at one week (r = -.260; p = .003) and six months after start 




Study Aim #3 
Aim #3 
Based on the sample data, to explore the likelihood that participant experience of 
FT predicts participant perception of distress and non-adherence to the treatment given 
orally.  
 
Aim #3: Analysis 
From frequency, distribution and univariate analysis of study data, both at one 
week and at six months from start of treatment given orally, there were no significant 
relationships between total COST scores and Distress Scores at either timepoint:  seven 
days post start of treatment (r = -.115, p = .276) and at six months post start of treatment 
(r - -.085, p = .405). (Table 4-6).  Therefore, a logistic regression model for FT level (via 
total COST scores) to predict perception of distress could not be calculated. 
COST instrument scores were statistically significant related to adherence at 
seven days post start of treatment (r = -.260, p = 003) and at six months post start of 
treatment (r - -.245, p = .005).   For both timepoints, there was a weak negative 
correlation, FT to adherence.   Since FT and adherence were the only two variables, FT 
level (via total COST scores) could not predict adherence to treatment, based on a logistic 










 n % 
Gender 136  
      Women 





Age 136  
      50-64 years old 





Living Status 136  
      Married/domestic partner 
      Single 
112 
  24 
(82.4%) 
(17.6%) 
Education 136  
      <12 the grade, some college 
      Completed college/grad school 
  48 











 n % 
Cancer Diagnosis 130  
    Chronic Lymphocytic Leukemia 54 (41.5%) 
    Multiple Myeloma 34 (26.1%) 
    Polycythemia Vera   5  ( 3.8%) 
    Essential Thrombosis   2   (1.5%) 
    Myelofibrosis   7   (5.4%) 
    Chronic Myelogenous Leukemia,       
         Prostate, Breast, Lung (1 each) 
 4   (3.1%) 
    No response 24 (18.5%) 
Oral cancer treatments 126  
For CLL:   
    Imbrutinib (Imbruvica®) 54 (42.8%) 
    Venetoclax (Venclexta®) 8  (6.3%) 
    Acalabrutinib (Calquence®) 3  (2.3%) 
For MM   
    Hydroxyurea (Hydrea) 9  (7.1%) 
    Lenalidomide (Revlimid®) 33 (26.2%) 
For myelofibrosis, polycythemia vera   
    Ruxolitinib (Jakafi®) 10   (8.0%) 
Other oral cancer treatments 13 (10.3%) 
   
Currently Receiving Tx Given Orally 128  
    Yes 
    No 
109 
  19 
(85.1%) 
(14.8%) 
On Treatment for Cancer Given Orally  136  
  Stayed on 
  Temporarily stopped 
  Never started 
118 
    4 




Stop other non ca meds 132  
    Yes 
    No 
    5 
127 
(  3.8%) 
(96.2%) 
Take some non ca meds 129  
    Yes 
    No 
    5 
124 
(  4.0%) 
(96.1%) 
Lower dose non ca meds 124  
    Yes 
    No 
    8 
 116 








 n % 
Health Insurance 130  
    Yes 
    No 
128 
   2 
(98.4%) 
(   1.5%) 
Insurance Carrier 120  
    Private/AARP 
    Medicare 
    Medigap 
    Medicare Advantage (b) 




  7 






Prescription Plan 130  
    Yes 
    No 
122 
    8 
(94.0%) 
(   6.1%) 
Prescription Coverage 116  
    Part D 
    Private 
    Part #, Tri Care (1 each) 
    Advantage 
  65 
  47 
    2 
    2 
(56%) 
(40.5%) 
   (1.7%) 
   (1.7%) 
Responsible for Cancer Cost 121  
    <20% of the cost 
    20-50% of the cost 
    50-100% of the cost  
    Co pay (no amount) 
    Clinical Trials 
    Grants 
    Donut, pay % overage 
    All OOP 
    Co pay $10/mon 
    Co pay $25/mon 
    Co pay $ 40/mon 
    Co pay $50/mon 
    Co pay $150/mon 
    Co pay $200/mon 
    Co pay $500/mon 
    Co pay $2000 
    No response/skipped 
  52 
  22 
   6 
  10 
    5 
    3 
    2 
    2 
    1 
    1 
    1 
    1 
    1 
    1 
    1 
    1 
   11 
(43.0%) 
(18.0%) 
















Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 = 
(5.1%); reduced dose other meds, 12 = (8.8%); insurance, n = 6 (4.4%); on drug 







 n % 
Employed now  125 % 
   Fulltime/Part-time 
   Not Employed 
  32 
  93 
(25.6%) 
(74.4%) 
Employed when started ca tx 124  
   Yes 
   No 
  67 
  57 
(54%) 
(46% 
Tx Affected Employment 122  
   Yes 
   No 
  42 
  80 
(34.4%) 
(65.6%) 
Income support 120  
   Self 
   Self/partner/others 
  28 
  92 
(24.0%) 
(75.5%)) 










   Yes 
   No 
  57 
  66 
(46.3%) 
(54.0%) 
% Support from 
Pharma/Advocate Groups 
125  
  <20% 
   20-50% 
  50-100% 
  Don’t know 
  Skipped 
  13 
    9 
  34 
  10 
  59 
(10.4%) 
(  7.2%) 
(27.2%) 
(    .8%) 
(47.2%) 
Monthly OOP costs 118  
    <$500/mon 
    >$500/mon 
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Missing data:  Employed now, n = 11 (8.1%); Employed when start tx, n =12 
(8.8%); Tx affected employment, n = 14 (10.3%); Income Support, n = 16 
(11.8%); Gross Income, n = 18 (13.2%); Received pharma help, n = 13 (9.6%); % 





Experience of Financial Toxicity 
COST Individual Item Scores 
Participant Perception Seven Days after Start of Cancer Treatment Given Orally 




Range Mean SD 

















I know that I have 
enough money in 
savings, retirement 
or assets to cover 
the cost of my 
treatment.  
(n = 117) 
27 
(23.1%) 






are more than I 
thought they 








I worry about the 
financial problems 
I will have in the 
future as a result 
of my illness or 
treatment.  
(n =97) 




I feel I have no 
choice about the 
amount of money I 
spend on care.   
(n= 118) 







Experience of Financial Toxicity 
COST Individual Item Scores 
Participant Perception Seven Days after Start of Cancer Treatment Given Orally 
Score range: 0-44 [n = responses; (%)] 
(continued) 
 
I am frustrated that I 
cannot work or 
contribute as much 












I am satisfied with 












I am able to meet 
my monthly 
expenses. (n =115) 
14 
(12.2%) 






I feel financially 











I am concerned 
about keeping my 
job and income, 
including work at 











My cancer or 
treatment has 
reduced my 
satisfaction with my 
present financial 
situation. (n= 118) 








I feel in control of 
my financial 
situation.  

















Experience of Financial Toxicity 
COST Individual Item Scores 
Participant Perception Six Months after Start of Cancer Treatment Given Orally 
Score range: 0-44 [n = responses; (%)] 
 
Total COST Score Range Mean SD 

















I know that I have 
enough money in 
savings, retirement 
or assets to cover 
the cost of my 
treatment.  
(n = 116) 
29 (25%) 19 
(16.3%) 






are more than I 
thought they would 
be.  
(n = 116) 
9 (7.8%) 17 
(14.6%) 




I worry about the 
financial problems 
I will have in the 
future as a 
result of my illness 
or treatment  
(n =116) 
6 (5.1%) 13 
(11.2%) 




I feel I have no 
choice about the 
amount of money I 
spend on care.  
(n = 115) 







Experience of Financial Toxicity 
COST Individual Item Scores 
Participant Perception Six Months after Start of Cancer Treatment Given Orally 
Score range: 0-44 [n = responses; (%)] 
(continued) 
 
I am frustrated that 
I cannot work or 
contribute as much 
as I usually do.  
(n = 116)  








I am satisfied with 
my current financial 
situation. (n = 118) 
38 
(32.2%) 






I am able to meet 
my monthly 
expenses  
(n = 118) 








I feel financially 











I am concerned 
about keeping my 
job and income, 
including work at 
home.  











My cancer or 
treatment has 
reduced my 
satisfaction with my 
present financial 











I feel in control of 
my financial 
situation.  


















Out of Pocket (OOP) Expenses 
Responses to Demographics Survey 
(Participants responding: n = 117) 
 
 n % 
Transportation 101   86.3% 
Hotel 35   29.9% 
Lost wages 23  19.7% 
Child care 3     2.6% 
OTC meds 67   57.2% 
Other:   
  Pet care 1   <1% 
  Prescription meds 1   <1% 
  Medical Marijuana 1   <1% 
  Meals when travelling 1   <1% 
  Flights 1   <1% 




Distress Thermometer  
(0-10 score) 
 
Levels of Distress 
 
 @ 1 week  
Post Start of 
Treatment 
 
@ 6 months 
Post start of 
Treatment 
 
 n % n % 
 92  97  
Low distress (1-4) 32 (35%) 39 (40%) 
Medium distress  
(5-7)  
15 (16%) 20 (21%) 
High distress (8-10) 39 (42%) 38 (39%) 
 
 
Missing data: Distress Thermometer: 7 days post start of tx, n = 44 (32.3%); 6 






Responses to Distress Thermometer Instrument 
(Participants responding = 115) 
 
 n %   n % 
Practical Problems    Physical Problems   
Child Care 1 <1%  Appearance 53 48.1% 
Housing 14 12.1%  Bathing/Dressing  8 7.0% 
Insurance/Financial 64 55.7%  Breathing 27 23.5% 
Transportation 18 15.7%  Changes in urination 17 14.8% 
Treatment Decisions 27 23.5%  Constipation 33 29.0% 
Family Problems    Diarrhea 41 35.7% 
Dealing with children  9 7.8%  Eating 34 30.0% 
Dealing with partner  28 24.3%  Fatigue 74 64.3% 
Ability to have children 4 3.5%  Feeling swollen 31 27.0% 
Family health issues 41 35.7%  Fevers 8 7.0% 
Treatment Decisions 44 38.3%  Getting around 37 32.1% 
Emotional Problems    Indigestion 37 32.1% 
Depression 53 46.1%  Memory/concentration 64 55.7% 
Fears 66 57.4%  Mouth sores 13 11.3% 
Nervousness 39 34.0%  Nausea  29 25.2% 
Sadness 54 47.0%  Nose dry/congested  35 30.4% 
Worry 82 71.3%  Pain  59 51.3% 
Loss of Interest in usual 
activities 
58 50.4%  Sexual 28 24.3% 
Spiritual/Religion 11 9.6%  Skin dry/itchy 61 53.0% 
    Sleep  66 57.4% 
    Substance use 7 6.1% 
    Tingling in hands/feet 47 40.1% 
    Other   
    Leg cramps 6 5.2% 
    Skin Cancer 1 <1% 
    Caregiver for Family 1 <1% 
    Infections 3 2.6% 
    Hot/Cold 1 <1% 
    Taste of Food 1 <1% 
    Falling 1 <1% 
    Skin Eruptions/Rash 4 3.5% 







Table 4-6  
Correlations between 
Total COST Score (Financial Toxicity)  
and Total Distress Thermometer Score 
 
 COST Score 
@ 7 days post  
start of Treatment 
(n = 119) 
COST Score 
@ 6 months post  
start of Treatment 





n 92 97 
p .276 .405 
r -.115 -.085 
 
COST = Comprehensve Score Financial Toxicity 
r = Pearson’s Correlation  
p = significance @ < .05    
NOTE:  No correlations are significant 
 
Missing data: COST scores 7 days post start of tx, n = 17 (8.8%); 6 mons post 
start of tx, n = 17 (8.8%) 
Missing data: Distress Thermometer: 7 days post start of tx, n = 44 (32.3%); 6 







Demographic variables to COST (Financial Toxicity) Scores  












n 136 136 136 136 
p .335 .509 .599 .771 
r .083 .057 -.046 -.025 
 
 
COST = Comprehensive Score Financial Toxicity 
r = Pearson’s Correlation  
 
Correlation is significant at the 0.05 level (2-tailed) 
NOTE:  No correlations are significant 
 








Demographic variables and COST (Financial Toxicity) Scores  













n 136 136 136 136 
p .207 .332 .829 .956 
r .109 .084 -.019 .005 
 
COST = Comprehensive Score Financial Toxicity 
r = Pearson’s Correlation  
 
Correlation is significant at the 0.05 level (2-tailed) 
NOTE:  No correlations are significant 
 





Table 4-9  
Correlations 
Clinical Variables to COST (Financial Toxicity) Scores  





















n 136 132 129 124 130 130 
p .249  .106 .504 .429 .366 .035 
r -.101 .142 -.059 -.072 -.080 -.185* 
 
COST = Comprehensive Score Financial Toxicity 
r = Pearson’s Correlation  
*Correlation is significant at the 0.05 level (2-tailed) 
 
 
Missing data: COST scores 7 days post start of tx, n = 17 (8.8%) 
Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 = (5.1%); 







Clinical Variables to COST (Financial Toxicity) Scores  
 (@ Six Months After Start of Treatment) 
(n = 117) 
 


















n 136 132 129 124 130 130 
p .243 .379 .508 .804 .631 .022 
r -.102 .078 -.059 .023 -.043 -.201* 
 
COST = Comprehensive Score Financial Toxicity 
r = Pearson’s Correlation  
*Correlation is significant at the 0.05 level (2-tailed) 
 
Missing data: COST scores 6 mon post start of tx, n = 17 (8.8%) 
Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 = (5.1%); 









Financial Variables to COST (Financial Toxicity) Scores  





COST = Comprehensive Score Financial Toxicity 
r = Pearson’s Correlation  
rs = Spearman’s Rank Order Correlation 
 
*Correlation is significant at the 0.01 level (2-tailed) 
 
Missing data: COST scores 7 days post start of tx, n = 17 (8.8%) 
Missing data: Employed now, n = 11 (8.1%); Employed when start tx, n =12 (8.8%); Tx 
affected employment, n = 14 (10.3%); Income Support, n = 16 (11.8%); Gross Income, n 
= 18 (13.2%); Received pharma help, n = 13 (9.6%); % help pharma n = 11 (8.1%); 

























n 125 124 122 120 117 123 125 118 
p .827 .941 .002 .207 .918 .791. .086 .216 
r -.020 .007 .282* -.116 -.010 .024 -.148 .115 
         
p        .005 





Financial Variables to COST (Financial Toxicity) Scores  



























n 125 124 122 120 117 123 125 118 
p .673 .902 .001 .060 .371 .578 .084 .102 
r -.038 -.011 .326* -.172 .083 -.052 -.149 .151 
         
p        <.001 
rs        .340* 
 
COST = Comprehensive Score Financial Toxicity 
r = Pearson’s Correlation 
rs = Spearman’s Rank Order Correlation  
*Correlation is significant at the 0.01 level (2-tailed) 
 
Missing data: COST scores 6 mons post start of tx, n = 17 (8.8%) 
Missing data: Employed now, n = 11 (8.1%); Employed when start tx, n =12 
(8.8%); Tx affected employment, n = 14 (10.3%); Income Support, n = 16 
(11.8%); Gross Income, n = 18 (13.2%); Received pharma help, n = 13 (9.6%); % 






Total COST Scores (Financial Toxicity)  
and Adherence 
 
 COST Score 
 @ 7 days post  
start of Treatment 
COST Score 
@ 6 months post  
start of Treatment 
Adherence   
n 119 119 
p .003 .005 
r -.260 -.245 
 
COST = Comprehensve Score Financial Toxicity 
r = Pearson’s Correlation  
 
Correlation is significant at the 0.05 level (2-tailed)    
NOTE:  Correlations are significant 
 
Missing data: Adherence, n =  8 (5.9%) 
Missing data: COST scores 7 days post start of tx, n = 17 (8.8%); 6 mons 





Pairwise Correlation Demographic Variables 
(n = 136) 
 
 Gender Age Living 
status 
Education 
Gender 1    
Age .301* 
(<.001) 





















Pairwise Correlation Clinical Variables 
(n = 136) 
 








































































* Correlation is significant at the 0.05 level (2-tailed) 
** Correlation is significant at the 0.01 level (2-tailed) 
 
Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 = (5.1%); 





































n = 125 124 122 120 117 123 125 118 
Employed 
Now 


















































































* Correlation is significant at the 0.05 level (2-tailed) 
** Correlation is significant at the 0.01 level (2-tailed) 
 
Missing data: Employed now, n = 11 (8.1%); Employed when start tx, n =12 (8.8%); Tx 
affected employment, n = 14 (10.3%); Income Support, n = 16 (11.8%); Gross Income, n 
= 18 (13.2%); Received pharma help, n = 13 (9.6%); % help pharma n = 11 (8.1%); 









Demographic Variables and Distress Thermometer Scores 
(@ Seven Days after Start of Treatment) 











n 136 136 136 136 
p .889 .913 .395 .389 
r -.015 -.012 -.090 .091 
 
r = Pearson’s Correlation  
 
Correlation is significant at the 0.05 level (2-tailed) 
NOTE:  No correlations are significant 
 




Demographic Variables to Distress Thermometer Scores 
(@ Six Months After Start of Treatment) 










n 136 136 136 136 
p .380 .484 .558 .317 
r .090 .072 -.060 .103 
 
r = Pearson’s Correlation  
 
Correlation is significant at the 0.05 level (2-tailed) 
NOTE:  No correlations are significant 
 







Clinical Variables and Distress Thermometer Scores  
(@ Seven Days After Start of Treatment) 
(n = 92) 
 
 


















n 136 132 129 124 130 130 
p .364 .306 .515 .189 .910 .897 
r .096 .109 .070 .144 -.012 .014 
 
r = Pearson’s Correlation  
 
Correlation is significant at the 0.05 level (2-tailed) 
NOTE:  No correlations are significant 
 
Missing data: Distress Thermometer: 7 days post start of tx, n = 44 (32.3%) 
Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 = (5.1%); 






Table 4-20  
Correlations between 
Clinical Variables and Distress Thermometer Scores  
(@ Six Months After Start of Treatment) 
(n = 97) 
 


















n 136 132 129 124 130 130 
p .254 .269 .267 .717 .928 .452 
r .118 .115 .115 .039 .009 .078 
 
r = Pearson’s Correlation  
 
Correlation is significant at the 0.05 level (2-tailed) 
NOTE:  No correlations are significant 
 
Missing data: Distress Thermometer: 6 mons post start of tx, n = 39 (29%) 
Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 = (5.1%); 








Financial Variables to Distress Thermometer Scores 
(@ Seven Days After Start of Treatment) 

























n 125 124 122 120 117 123 125 118 
p .441 .611 .360 .168 .773 .052 .165 .612 
r .084 .055 -.100 .152 -.032 .210 .230 .057 
 
r = Pearson’s Correlation  
 
Correlation is significant at the 0.05 level (2-tailed) 
NOTE: No correlations are significant 
 
Missing data: Distress Thermometer: 7 days post start of tx, n = 44 (32.3%) 
 
Missing data: Employed now, n = 11 (8.1%); Employed when start tx, n =12 (8.8%); Tx 
affected employment, n = 14 (10.3%); Income Support, n = 16 (11.8%); Gross Income, n 
= 18 (13.2%); Received pharma help, n = 13 (9.6%); % help pharma n = 11 (8.1%); 







Financial Variables to Distress Thermometer Scores 
(@ Six Months after Start of Treatment) 

























n 125 124 122 120 117 123 125 118 
p .953 .909 .939 .305 .861 .069 <.001 .358 
r -.006 .012 .008 .111 .019 .193 .336* -.100 
 
r = Pearson’s Correlation  
 
* Correlation is significant at the 0.01 level (2-tailed) 
 
Missing data: Distress Thermometer: 6 mons post start of tx, n = 39 (29%) 
Missing data: Employed now, n = 11 (8.1%); Employed when start tx, n =12 
(8.8%); Tx affected employment, n = 14 (10.3%); Income Support, n = 16 
(11.8%); Gross Income, n = 18 (13.2%); Received pharma help, n = 13 (9.6%); % 




 Demographics Variables and Adherence 










n 136 136 136 136 
p .905 .852 .257 .671 
r -.011 -.017 .101 .038 
 
r = Pearson’s Correlation  
 
Correlation is significant at the 0.05 level (2-tailed) 
NOTE:  No correlations are significant 
 




Table 4-24  
Correlations Between 
Clinical Variables and Adherence 
(n = 128) 
 


















n 136 132 129 124 130 130 
p .006 .756 <.001 .794 .934 <.001 
r .243* .028 .368* -.024 .007 .345* 
 
r = Pearson’s Correlation  
* Correlation is significant at the 0.01 level (2-tailed) 
 
Missing data: Adherence: n = 8 (5.9%) 
Missing data: Stopped other meds, n = 4 (2.9%), took some of other meds, 7 = 
(5.1%); reduced dose other meds, 12 = (8.8%); insurance, n = 6 (4.4%); on drug 





Table 4-25  
Correlations Between 
Financial Variables and Adherence 


























n 125 124 122 120 117 123 125 118 
p .583 .153 .786 <.001 .045 .161 .051 .351 
r -.050 .131 .025 -.055** .188* .080 .173 -.088 
 
r = Pearson’s Correlation  
* Correlation is significant at the 0.05 level (2-tailed) 
** Correlation is significant at the 0.05 level (2-tailed) 
 
 
Missing data: Adherence: n = 8 (5.9%) 
Missing data:  Employed now, n = 11 (8.1%); Employed when start tx, n =12 
(8.8%); Tx affected employment, n = 14 (10.3%); Income Support, n = 16 
(11.8%); Gross Income, n = 18 (13.2%); Received pharma help, n = 13 (9.6%); % 





















This chapter presents a discussion of a descriptive, cross-sectional study about 
cancer patients and their financial toxicity (FT) experience and whether that experience 
affected their level of distress or adherence to treatment.  This chapter provides a 
scholarly context about the study’s results, describing the participants, their FT 
experience and relationships among FT-associated variables, perception of distress and 
adherence to prescribed cancer treatment given orally. 
The study’s data were collected on-line from 136 participants, who were members 
of the patient education/advocacy community, Patient Power®.  Participants were self-
identified as diagnosed with a malignancy and prescribed a cancer treatment given orally.  
Participants completed three study instruments to better describe themselves and their FT 
experience: a Demographics Questionnaire, the Comprehensive Score for Financial 
Toxicity (COST) and the Comprehensive Cancer Network (NCCN) Distress 
Thermometer (DT).  
Healthcare Costs 
The participants in this study confirm what is known in clinical practice--that the 
challenges associated with FT affect whether patients can maintain their health care 
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coverage (Conway, 2019; Carrera, Kantarjian & Blinder, 2018; Warsame et al., 2018; 
Goldstein, 2017; KFF, 2017). 
The burden of FT includes--but is not limited to--access to care, coverage for 
care, maintaining sources of income and the impact of FT on interpersonal relationships 
(Collado & Brownell, 2019; Salsman, Bingen, Barr & Freyer, 2019; Thom & Benedict, 
2019; Honda et al., 2018; Knight et al., 2018;  Peppercorn, 2017). 
The experience of FT is especially burdensome for individuals diagnosed and 
treated for cancer (NCI, 2019; Mohmmed & El-sol, 2018; Winkfield et al., 2018; Shen, 
Zhao, Liu & Shih, 2017). As experienced by cancer patients, the focus about FT may be 
due to the disruptive impact of cancer on the patient (Allcott et al., 2019; Yabroff, et al., 
2019), the high cost of treatments (Cole, Jazowski & Dusetzina, 2019; Farano, & 
Kandah, 2019; Giuliani & Bonetti, 2019; Tran & Zafar, 2018; Truong et al., 2019; 
Prasad, de Jesus & Mailankody, 2017) and the long-term impact that FT has on cancer 
patients and their caregivers (Banegas et al., 2019;  Bradley, 2019; Cole et al., 2019; 
Goldstein, 2017).    
 
FT and Study Results 
Demographics 
This study explored the impact of FT on a sample group of cancer patients, 
prescribed treatments given orally.  The majority of participants had cancer diagnoses 
associated with standard-of-care treatments that were especially high in cost; the majority 
of participants were diagnosed with the chronic hematologic malignancies myelogenous 
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leukemia (CLL) and malignant myeloma (MM)  (Hilal, Betcher & Leis, 2018; Schneider, 
Steinbrecher & Stilgenbauer, 2019).  For three-months of treatment for these diagnoses, 
the range of cost (without insurance coverage, co-payments, deductibles, discounts or 
other factors affecting the cost of treatment) is $15,000-$50,000 (B. Chan, personal 
communication, October 10, 2019). 
As documented in other studies about patients diagnosed with chronic 
hematologic malignancies, these study participants received relatively new treatments, 
representing treatment breakthroughs (Farano & Kandah, 2019; Hilal et al., 2018).  For 
these study participants as with others diagnosed with these hematologic malignancies, 
their disease is considered a chronic condition, so they can be on treatment for a long 
time (Schneider et al., 2019; Peppercorn, 2017).  Considered standard treatments for 
study participants’ malignancies, the most frequently reported treatments were imbrutinib 
(Imbruvica®), lenalidomide (Revlimid®) and ruxolitinib (Jakafi®) (Schneider et al., 
2019; Hilal et al., 2018).    
 Moreover, over time, when one treatment becomes ineffective, providers may 
choose to switch treatments, once again with the option of prescribing treatments with 
relatively new FDA approvals (Farano & Kandah, 2019; Giuliani & Bonetti, 2019).  
Therefore, additional new treatments for these chronic hematologic malignancies can be 
costly (Cole et al., 2019; Truong et al., 2019).  In addition, new treatments (in oral 
formulations) are early in their FDA approval period so are at high cost, since 
pharmaceutical companies want to recoup the cost of drug development (Banegas et al., 
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2019; Califf & Slavitt, 2019; Collado & Brownell, 2019; Giuliani & Bonetti, 2019; Tay-
Teo, Ilbawi, & Hill, 2019; Truong et al., 2019;  Yabroff et al., 2018; Prasad et al., 2017). 
In this study, the sample population of participants was older, well educated, with 
stable social supports and means or strategies to pay for their treatments.  The majority of 
participants in this study were covered by adequate insurance or had supplemental health 
care insurance policies.  This study’s overall participant profile matches a significant 
cohort of the CLL and MM patient population, who have found ways to continue on their 
long-term treatments (Allcott et al., 2019; Yabroff et al., 2018; Schneider et al., 2019). 
More women than men were represented in the study sample (women: n =75, 
51.1%;  men: n = 61, 44.9%).   With actuarial tables confirming that women live longer 
than men, women’s FT experience may be perceived as more acute or at a higher level.  
This more profound female FT experience may be due to more prolonged financial stress;  
that stress can build due to age and be exacerbated by less than adequate or no health 
insurance coverage (Shen, et al., 2017; Gordon et al., 2017). 
The overwhelming majority of the study’s sample population did not skip cancer 
treatments given orally due to FT.  In addition, participants reported that they rarely 
adjusted prescribed non-cancer medications to maintain and pay for their cancer 
treatment.  This was in keeping with what has been published about FT experienced by 
cancer patients and whether they adjusted their cancer therapy so they could stay on 




Two thirds of the study’s participants reported gross income of  <$100,000/year 
with the remaining third reporting gross income >$100,000/year.  (In 2017, the average 
median household income in the U.S. was projected at $57,652 (US Census Bureau, 
2019).   
For the general population of cancer participants receiving treatments given 
orally, not all cancer patients have the option of receiving treatment given orally or the 
means to pay for new cancer treatments in oral form (Hilal et al., 2018).    Thus, this 
study population benefitted from higher gross incomes, insurance coverage that, in 
general, paid for the cost of their treatments and/or pharmaceutical company-funded 
programs, which helped cover their treatment expense. These results suggest that this 
study’s sample population may not be representative of the experience of other cancer 
participants treated with high-cost cancer treatments (Farano & Kandah, 2019).  But this 
study’s results do suggest that the factors of adequate insurance, access to treatment 
support (from pharmaceutical companies and foundations) and an adequate or 
temporarily interrupted income stream (employment) mitigate the impact of FT when 
patients are prescribed high-cost treatments (Macmillan, 2019, Shen et al., 2017) 
FT Experience 
This study’s participants experienced various levels of FT and at various times, as 
documented by the COST instrument scores and specific responses to the COST 
instrument questions.  In this study, approximately one third of participants reported their 
perception of FT was quite a bit or very much, based on COST scores at both seven days 
post start of treatment and six month post start of treatment.    
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These results concur with other studies of cancer patients and FT.  For studies that 
used the COST instrument to further describe and clarify the FT experience, those studies 
reported that certain cancer patients experienced higher levels of FT during some period 
of their cancer treatment  (Bouberhan et al., 2019; Ezeife et al., 2019; Ferrell et al., 2018; 
Honda et al., 2018).   
Of note in this study, study participants were asked about their perceptions of FT 
at two timepoints, which other studies have not explored in their study designs.  For this 
study, the level of total FT scores was slightly higher six-months after treatment began 
compared to seven days after treatment began.   These findings concur with other studies, 
which report that cancer patient FT can increase over time, especially with the stress of 
continuing, high-cost therapies, as well as the chronic impact of a cancer diagnosis on 
daily life (Thom & Benedict, 2019; Carrera et al., 2018; Shen et al., 2017). 
In this study from the COST instrument, these specific FT responses were scored 
higher at both the seven day and six month post start of treatment timepoints: “Feel no 
choice about cost of care”, “worry about future financial problems due to illness”, 
“higher than anticipated out of pocket medical expenses”, “reduced satisfaction in current 
financial situation due to cancer treatment”, “ability to meet monthly expenses”  and 
“overall financial stress”.  These responses were in keeping with findings from other 
studies about FT and the cancer patient experience (Ezeife et al., 2019; Carrera et al., 




Out of Pocket Expenses for Treatment 
About two thirds of study participants reported OOP costs < $500/month with the 
remaining third of participants reporting OOP costs >$500/month. Studies have reported 
that OOP health insurance co-pays and deductibles are rising (KFF, 2017).  For cancer 
patients, OOP costs can be extensive and unpredictable (Conway, 2019).   
Participants in this study also concur that transportation costs (gas and parking) 
are the most often cited OOP costs related to cancer treatment (Leopold et al., 2019; 
Rosenzweig et al., 2019).  Study participants also noted they experienced higher copays 
and deductibles associated with their insurance coverage and treatment (Conway, 2019;  
KFF, 2017).  Other OOP costs from this study’s participants (loss of income, child care, 
over-the-counter medications), are similar to OOP costs reported in other FT studies 
(Leopold et al., 2019; NCI, 2019; Buttner et al., 2018). 
Financial Support for Treatment 
For study participants responding about receiving financial support for treatment 
from pharmaceutical, foundation or other non-insurance sources, they were generally 
split between those who received support (n = 57, 46.3%) and those who did not receive 
support (68, 54.0%).   Cancer patients’ source of additional financial support and how 
much financial support goes to the cost of treatment have not been rigorously studied 
(MacMillian, 2019).  In this study, approximately half of study participants did not 
respond to the question about the percentage of financial support received from non-
insurance sources.    Still in clinical practice, pharmaceutical, foundation or other non-
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insurance sources significantly augment the OOP expenses of cancer treatment when 
patients’ insurance coverage does not cover the cost of treatment (MacMillan, 2019). 
In this study for participant perception of distress related to demographic, clinical 
and financial variables, the only statistically significant relationship was perception of 
distress at six months post start of treatment and the percentage expense supported by 
pharmaceutical companies or foundations (r = .336, p = .001). This suggests that over 
time, the level of distress can be affected by the level of pharmaceutical or foundation 
financial support (MacMillan, 2019). 
Distress Experience 
More than a third of study participants reported high distress due to FT at both 
one week post start of treatment and at six months post start of treatment.  Distress due to 
just FT is difficult to measure, when the cancer experience in its entirety is stressful.   
For this study at the two timepoints, there was no statistically significant 
relationship established between FT and participants’ perception of distress.  Still other 
studies concur that FT is a prevalent source of distress for cancer patients so FT has 
clinical significance (Ezeife et al., 2019; Thom & Benedict, 2019; Carrera et al., 2018).   
Worth noting in this study at both timepoints, almost a third of participants did 
not respond to the study’s distress instrument.  This, once again, suggests that identifying 
FT as a distinct source of stress to cancer patients is difficult (Thom & Benedict, 2019).   
In this study, the non response to the distress instrument may be due to the participant’s 
own difficultly in separating FT-related stress from the participant’s general distress 
about the cancer experience (Rosenzweig et al., 2019; Thom & Benedict, 2019).  It may 
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also be due to not wanting to respond to an instrument measuring distress (Vanhoose et 
al., 2015; Mitchell, 2007).  
Adherence to Treatment 
Most study participants reported that they adhered to their prescribed cancer 
treatment given orally and did not stop, interrupt or alter their prescribed treatment 
regimen because of FT.  These findings are in keeping with studies that show despite the 
stress brought on by FT, treatment adherence is high (Gupta et al., 2019).   In this study, 
COST instrument scores, representing FT, had a weak negative correlation related to 
adherence at seven days post start of treatment (r = -.260, p = 003) and at six months post 
start of treatment (r - -.245, p = .005).   But in this study due to the sample size, FT could 
not be statistically established as a predictor of adherence. 
As identified in other studies to maintain treatment adherence, participants in this 
study mobilized a multitude of strategies to support adherence: intact and robust health 
insurance coverage; coverage from supplemental health insurance policies; drug coverage 
plans that cover specialty medications (i.e. new cancer treatments given orally); financial 
support from pharmaceutical, foundation or other non-insurance sources to cover 
treatment costs; and the ability to adequately cover OOP costs of treatment (sufficient 
gross income, sources of regular income) (Cole et al., 2019; Gupta et al., 2019; Taylor, 
2019; Rosenzweig et al., 2019, Honda et al., 2018;  Knight et al., 2018).  
In this study, adherence to treatment was weakly correlated to income support (r = 






In the context of FT, this study’s findings suggested weak relationships at both 
seven days and six months post start of treatment, based on COST scores and whether 
participants had a drug plan, whether they were employed and whether they adhered to 
treatment.  Several studies of cancer patients have identified similar FT-associated 
relationships (Schneider et al., 2019; Taylor, 2019; Gilligan, Alberts, Roe & Skrepnek, 
2018). 
In this study describing participants’ experience of FT and demographic variables, 
there were weak relationships associated between gender and age; gender and living 
status; and education to living status.  These relationships may not be consistent for all 
cancer patients and their experience with FT (Thomas et al., 2019). 
From participants’ experience with FT and clinical variables, this study suggests 
weak relationships between  
• lowering the dose of non-cancer medications and taking some prescribed 
non-cancer medications, as prescribed 
• being covered by insurance and being covered by a drug plan  
• adherence to treatment and having a drug plan  
• employed now and employed when started treatment 
• treatment affected employment and income support 
• income support and gross income 




• gross income and percentage of help received from pharmaceutical 
companies/foundations 
• received help from pharmaceutical companies/foundations and OOP 
monthly costs   
and  
• percentage help from pharmaceutical companies/foundations and OOP 
monthly costs. 
In this study, a moderate correlation was established between skipping cancer 
treatment and taking some prescribed non-cancer medications (r = .600, p = < .001).  This 
study also indicated a high correlation between pharmaceutical/foundation support and 
percentage help offered participants from those sources (r = .869, p = .001);  
For all the study’s intra-variable relationships listed above, these relationships 
confirm that FT issues are entwined and affect the overall FT experience (Ezeife et al., 
2019; Gupta et al., 2019; MacMillan, 2019; Renner, Burotto & Rojas, 2019; Thomas et 




Summary: FT and Study Results 
This descriptive, cross-sectional study included participants diagnosed with 
chronic hematologic malignancies, treated with treatments given orally.  Therefore, for 
their long-term cancer treatment, these study participants received high-cost cancer 
treatments, which affected their experience with FT, distress associated with FT and 
adherence to prescribed treatments. 
Confirming previous study findings in the literature, this study’s patient 
population experienced various levels of FT and at various times.  In this study, 
approximately one third of the participants reported that FT was quite a bit or very much 
both at seven days post start of treatment and six month post start of treatment.    
Distress associated with FT can be an issue although FT as a distinct source of 
distress was not confirmed in this study. To accommodate issues of FT, study participants 
received support from pharmaceutical, foundation or other non-insurance sources. They 
also were able to cover the cost of their treatment due to having robust insurance 
coverage, adequate income streams and the ability to cover OOP costs.  
In this study, despite the patient’s perception of FT at both one week post start of 
treatment and at six months post start of cancer treatment given orally, adherence to 
cancer treatment was largely not affected. 
Finally, this study’s findings concur that the FT experience for cancer patients is 
associated with many variables, which have intertwined relationships (Ezeife et al., 2019; 






This study’s findings have several limitations; these limitations affect whether the 
findings are applicable or generalizable to the FT experience of all cancer patients. 
Study Design 
Study limitations included the study design.    The study was a descriptive, cross-
sectional design study, seeking participants via a convenience sample from one on-line 
cancer patient education/advocacy group site.  The participants were self-described as 
diagnosed with cancer and prescribed treatment given orally.  Because of the study 
design, the profile of each participant could not be verified so the study’s data, 
representing the experience of cancer patients and FT, also could not be verified.  
The study requested that participants respond to the study’s three measurement 
instruments, relaying their perceptions about FT at two timepoints.   Choosing these 
particular timepoints was arbitrary.  In addition, study data relied on participants 
determining perceptions from their past, which could have been inexact, exaggerated 
and/or reliant on interpretations from vague memories. 
Sample Population 
In general, the participant sample was small in number, older, highly educated, 
adequately insured, benefitted from stable social supports, had adequate income streams 
and diagnosed with a chronic cancer diagnosis.  The participants were asked to respond 
to their experience associated only with their cancer treatment prescribed orally.  Because 
of their cancer diagnosis and their cancer treatments prescribed orally, those treatments 
had higher costs. 
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Study participants were English speaking, had access to the internet and were 
asked to respond to study questionnaires posing questions about complex concepts—FT 
and distress.   Although the sample population was recruited anonymously, the 
participant responses could have been biased toward what they assumed would be the 
outcomes of the study (i.e. everyone suffers from FT; everyone has had an extreme FT 
experience.) 
Participants in the study were not asked about their culture, ethnicity or sexuality.  
Therefore, those characteristics were unknown and so could not be reported.  Because 
this information was not captured, the interpretations of study findings are limited.  
Instruments in Study 
The Comprehensive Score for Financial Toxicity (COST) instrument is a 
relatively new instrument to measure FT and has been tested valid with advanced cancer 
patients (deSouza et al., 2017, 2014).  Its reliability and validity as a measurement 
instrument has not been studied in many populations with various diagnoses, stages of 
disease, treatment side effect profiles and experiences of FT (Bouberhan et al., 2019; 
Ezeife et al., 2019; Honda et al., 2018). 
The National Comprehensive Cancer Network (NCCN) Distress Thermometer 
(DT) has been widely studied and used to evaluate distress in cancer patients.  However, 
its reliability and validity as an instrument when administered online has not been 
thoroughly tested (NCCN, 2018). 
The study’s Demographics Questionnaire, administered on-line and focused on 
categorial responses to questions, was developed so it would be easy for participants to 
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complete.   There was no reliability or validity testing of the questionnaire. Because the 
questionnaire requested broad responses to sensitive topics (gross income, specifics about 
the experience of FT, financial support to cover the costs of treatment), captured study 
data may be too broad to determine FT distinctions related to the FT experience, 
demographic and clinical variables, FT association with distress and FT association with 
adherence to treatment.   In addition, this study’s instruments did not capture the patient’s 
self-assessment of severity or stage of illness, which would impact responses for FT, 
distress and adherence. 
In relation to the study’s three instruments, participants may have been reluctant 
to complete all or part of the instruments’ questions since some questions were about 
sensitive topics. Among those sensitive topics was the experience with FT, the ability to 
pay for treatment, the need to secure financial resources to supplement the expense of 
treatment and distress during cancer treatment. 
Clinical Practice Implications 
This study results suggest several implications for practice. 
Despite FT as a relatively newly-recognized stress in the cancer patient’s 
experience, FT as a form of stress can occur in varying degrees, depending on the patient 
and caregiver circumstances (Thomas et al., 2019; Carrera et al., 2018).  The ability for 
the cancer patient and caregivers to function depends on a combination of physical, 
psychosocial and spiritual factors (Knight et al., 2018).  When and whether FT affects 
patients is due to the dynamic, complex experience of cancer as a disease, as well as the 
experience of being treated for cancer (Thomas et al., 2019).  With FT contributing to 
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patient and caregivers stress, FT affecting care may be anticipated (Rosenzweig et al., 
2019; Thom & Benedict, 2019; Carrera et al. 2018).  It may also be addressed with the 
expertise of those who can problem-solve the patient’s healthcare financial status (Carr & 
Rosato, 2019; Sherman & Fessele, 2019; Berry et al., 2018).  And just as with other 
stresses, FT can be managed as part of the plan of care (NCCN, 2018). 
As with all stresses associated with the care of cancer patients and caregivers, the 
nurse-- as a member of the interdisciplinary care team--can make a significant impact to 
address FT. 
Nursing Care 
Assessment.  As a standard of care, FT is becoming a component of the nurse’s 
clinical assessment (Carr & Rosato, 2019). 
As a part of a clinical assessment initiated or continued by the clinical nurse, FT 
assessment does not need to be overly intrusive or involved. The assessment can include 
a few questions to start a conversation about FT issues or continue that conversation as 
treatment proceeds. Then the conversation can continue as the plan of care continues or 
changes (Carr & Rosato, 2019).   
The foundation for a FT-associated clinical assessment begins with questions 
similar to those listed in the COST instrument (deSouza et al., 2017, 2014).  At its 
foundation, a nurse-initiated FT assessment generates information from the patient about 
the patient’s health insurance, sources of income, OOP costs and the physical and 
psychological effects of FT (Katz, 2018). 
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Referrals. Any effective care of patients experiencing FT requires support and 
counsel from those who have expertise about healthcare coverage and financial issues 
(Sherman & Fessele, 2019; Berry et al., 2018).  In academic healthcare centers, 
comprehensive cancer centers and large health care systems, that expertise has become 
available to patients through financial counselors and/or specially-trained nurse 
navigators, social workers and lay patient navigators (Carr & Rosato, 2019).   
Nurses who provide direct care to patients can be the conduit to financial 
counselors (Nipp, Sonet & Guy, 2018).   As members of the interdisciplinary team, 
nurses can best care for patients by knowing available resources, connecting the patient 
with effective financial-support resources and ensuring that patients receive information, 
support and direction so that FT is addressed (Sherman & Fessele, 2019). 
Support. In relation to the cancer patient’s care plan, the nurse remains a reliable 
source of support, providing patient education, psychosocial support and strategies for 
problem solving (Carr & Rosato, 2019; Thomas et al., 2019; Ferrell et al., 2018)  As this 
study’s findings suggest, providers who are aware of the patient’s FT issues can better 
intervene to provide effective support (Bradley, 2019).  
Decision Making 
As the study’s results confirm, FT contributes to patients’ uncertainty related to 
the cancer diagnosis, treatment plan and life expectancy.  Since studies have raised the 
visibility of FT as a stress for cancer patients, several decision-making models have been 
proposed to open up the discussion about treatment and financially-based pros and cons 
about treatment options (Chino et al., 2019; Leopold et al., 2018; Gidwani-Marszowski et 
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al., 2018;  Bien et al., 2017).   These proposed frameworks may support transparency 
between providers and patients about treatment options toward shared decisions about 
treatment (Nipp et al., 2018).    
The role of the provider, opening up the process of decision making, has been 
studied, focusing on changing the hierarchy of information, traditionally in the sole 
control of the provider. These revised models attempt to shift decision-making to both the 
provider and patient, based on the patient’s preferences (Warsame et al., 2019).  These 
evolving decision-making frameworks intend to broaden treatment discussions—
including issues of the cost of care (Dine, Masi & Smith 2019; Doshi et al., 2019; Hong, 
Matusiak & Schumock, 2018).   
However, these decision-making frameworks are limited since providers often do 
not know the cost of the therapies they recommend (Farano & Kandah, 2019). And 
providers typically do not have access to basic information about the patient’s finances 
related to treatment decisions.  In general, providers do not know the patient’s individual 
insurance coverage benefits or options for supplemental financial support for care (Dine 
et al., 2019).  Moreover, there is no guarantee that the patient understands his or her 
health care financial information or status (Nipp et al., 2018).   
Frameworks and decision-making tools focus on patient choice (Seidman, Masi, 
Gomez-Rexrode, 2019; Bien et al., 2017), value of treatment (Doshi et al., 2019; Leopold 
et al., 2019; Gidwani-Marszowski et al., 2018), cost of care (Dine et al., 2019, Truong et 
al., 2019; Yu, Eton & Garrison, 2019), patient expectations (Hong et al., 2018) 
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information provided (Warsame et al., 2019), or a combination of the above (Doshi et al., 
2019, Gidwani-Marszowski et al., 2018, Hong et al., 2018). 
Future Research 
This study’s findings suggest directions for future research to better understand 
the FT experience, formulate FT standards of care and to establish clinical FT policies 
related to the care plan (Thomas et al., 2019).  Questions remain about FT and cancer 
patients—when it occurs, how best to address it, what resources can be mobilized over 
time and how to mitigate the high cost of cancer medications and treatment. What are the 
most effective and sensitive clinical interventions that provide patients and their 
caregivers with information, support and ways to problem solve? (Berry, Deming & 
Danaher, 2018). 
Opportunities for FT Research 
Among opportunities for FT research are cancer patients at risk for FT (Rupper, 
2018), FT challenges they face (Winkfield et al., 2018), patients with limited or 
interrupted incomes due to their diagnoses (Allcott et al., 2019; Collado & Brownell, 
2019), intense FT flashpoints during the continuum of care (Yu et al., 2019), treatment 
protocols that increase FT (Cole et al., 2019) and advocacy strategies (Thomas et al., 
2019). 
To address FT experienced by patients and caregivers, nurse researchers—as 
members of interprofessional teams—can identify, then investigate interventions that 
result in better patient outcomes (Thomas et al., 2019; Mohmmed et al., 2018).  These 
outcomes suggest that the standard of care requires FT expertise in the plan of care 
(Bradley, 2019; Sherman & Fessele, 2019).  Studies are needed about the merit of the 
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designated financial navigator role (Sherman & Fessele, 2019; Thom & Benedict, 2019; 
Berry et al., 2018), financial experts for patients at FT risk (Sherman & Fessele, 2019), 
financial expertise to address FT at specific timepoints (Berry et al., 2018), the need for 
comprehensive healthcare coverage (Conway, 2019) and strategies to pay for the cost of 
care (Cole, et al., 2019; Yu et al., 2019). 
Survivorship 
Cancer survivors present distinct FT implications (Benagas et al., 2019, Coughlin 
& Dean, 2019, Yabroff et al., 2019).    Survivors face FT issues related to extended 
treatment costs and sacrifices to pay for long-term or recurrent disease (Chino et al., 
2019;  Peppercorn 2017; Prasad et al., 2017). They are challenged to secure adequate 
healthcare insurance coverage and pay higher insurance premiums (Coughlin & Dean, 
2017; KFF, 2017).  They are concerned about their ability to keep working and maintain 
an income stream (Pearce et al., 2019).  And they need ongoing support and new 
resources to access care (Benagas et al., 2019, Pearce et al., 2019, Salsman et al., 2019,  
Yabroff, et al., 2019;  Zahnd et al., 2019). 
Federal Policy and Drug Costs 
Despite market forces that affect the cost of drugs in the U.S., the federal 
government’s influence over drug prices is significant, related to its ability to establish 
price controls or to negotiate prices for a large swath of patients covered by government-
supported health care (Blumenthal, 2016). 
With access to affordable, quality health care remaining a #1 priority of 
consumers in the U.S., the high cost of prescription drugs is just one of many health care 
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issues requiring a solution (Speaker, 2019).  Since the price of drugs in the U.S. can be 
twice the cost of drugs in other wealthy countries (Blumenthal, 2016), the public’s call 
for legislative remedies is persistent even while effective strategies to navigate barriers 
remain elusive (Stone, 2019; Sweeney, 2019; Walter, 2019) 
Federal policies that affect drug prices are very complex.  The challenge to 
decipher policies and determine who or what is influencing the cost of drugs contributes 
to the complexity.  Specific issues associated with federal policy include questions 
regarding how drug prices are determined, which drug prices can be negotiated, the 
extent of rate hikes, the transparency of billing and limitations or restrictions on 
pharmacy formularies (Horvath, 2018; KFF, 2019; Stone, 2019).   
Moreover, momentum to support any given legislative or policy proposal is fluid, 
affected by coalitions representing a wide array of players and agendas: health care 
facilities, health care providers, consumer advocacy groups, political parties, 
pharmaceutical companies and the government itself (Kodjak, 2018; Stone, 2019; Walter, 
2019). 
Legislative and Regulatory Initiatives 
Legislation to impact the cost of drugs is generated by Congress.  Legislation 
establishes broad, general laws that direct policy.  Regulations are generally written and 





An example of drug cost legislation proposed in the 116th Congress session of 
Congress (2019-2020) is HR-3, The Lower Drug Costs Now Act (Speaker, 2019).  
Among the provisions of HR-3 is a requirement to change laws that currently prohibit the 
Centers for Medicare & Medicaid Services (CMS) from negotiating prescription drug 
prices for its Medicare beneficiaries (Feke, 2019; McCaughan, 2017).  For Medicare 
beneficiaries, HR-3 proposes that CMS negotiate the price of certain drugs, including 
insulin and selected drugs that do not have generic equivalents since the government 
already can negotiate prices for federally supported Medicaid programs and the Veterans 
Administration (Feke, 2019; McCaughan, 2017). Many of the targeted drugs in HR-3 are 
for drugs most commonly prescribed for Medicare beneficiaries.    
Another component of HR-3 calls for setting maximum drug price ceilings for 
certain drugs and to allow a new framework for cost sharing when drug prices hit a pre-
determined threshold (Speaker, 2019). 
Although HR-3 does not target specialized cancer drugs in the legislation, efforts 
to curb specialized cancer drug prices start with winning the battle about sensible drug 
pricing for common prescription drugs (Stone, 2019; Sweeny, 2019). 
Regulations 
In general, regulations that address drug prices are the purview of the U.S. 
Department of Health and Human Services (DHHS), specifically through its agencies, the 
Centers for Medicare and Medicaid Services (CMS) and the Food and Drug 
Administration (FDA) (CMS.gov, 2019; Waxman et al., 2019).  
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FDA rules that explicitly impact cancer drugs include those addressing the 
development and approval of new drugs, and more specifically patents and exclusivity 
rights. The American Association of Clinical Oncology (ASCO), the professional society 
of clinical oncologists, has opposed regulations “extending market or data exclusivity 
periods” for a wide array of new cancer treatments, classified as small-molecule, generic, 
orphan, and biologic drugs (ASCO, 2019).  ASCO also has joined other patient advocacy 
groups, opposing Pharmacy Benefit Management (PBM) companies (third party 
prescription drug administrators), whose initiatives attempt to control cancer treatment 
costs but limit the ability of providers to prescribe appropriate and effective treatments 
for patients (ASCO, 2019).  (In 2017, PBM companies managed prescription benefits for 
an estimated 85% of health insurance benefits for those with public and private health 
insurance plans (NASEM, 2017).) 
The DHHS has also proposed revising regulations associated with improving 
transparency of drug costs, so that visibility of those costs would encourage negotiation 
and produce fewer surprises to consumers.  Those regulations would eliminate bills for 
the costs of care that were never discussed or determined before care was rendered.   
These efforts have been initiated to establish more rational “Balanced Billing”. 
“Balance Billing” usually is defined as billing a patient for the difference between the 
total cost of services being charged and the amount the insurance pays.   In reference to 
high cancer drug costs, revisions in “Balanced Billing” regulations would protect the 
patient from exorbitant bills when patients must go out of their insurance network for 
care and pay for that non-covered care.  For oncology patients, these situations occur 
112 
 
when their standard of care requires treatment that includes specialized cancer drugs not 
covered by their insurance.  However once again, progress toward support of revised 
regulations has been thwarted by the Courts, who have, to date, agreed with the 
pharmaceutical industry argument that revised regulations represent regulatory overreach 
(Stone, 2019; Sweeney, 2019). 
Federal Policy and Values 
So, in the long run, to pass legislation that has any effect on the cost of drugs, 
lawmakers--representing the electorate—must deal with what society values.  That focus 
on values includes what the electorate determines as fair—or even acceptable—as larger 
questions loom about a broken, inefficient health care system (Sweeney, 2019). These 
questions pit all sides in economic, legal and moral power struggles.   And from these 
struggles, it remains to be seen what drug cost changes can occur in a partisan political 
climate. 
Conclusion 
The experience of FT is an additional stress to cancer patients and their 
caregivers, especially during treatment, but also throughout the continuum of care.  The 
FT experience has many components, and is distinct for each individual, depending on 
the patient’s diagnosis, treatment plan, cost of treatment and clinical and financial factors.  
For any given patient when treatment begins and as it continues, FT may affect the 
patient’s perception of distress and adherence to treatment. 
This study’s findings characterized the FT experience, its timing and possible FT 
management strategies. These findings contribute to the ongoing clinical foundation 
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Appendix B  
Study Blurb 
You are invited to be a participant in a research study conducted by Ellen Carr, RN.  Ellen is 
a clinical oncology nurse.  She is also a doctoral student at the Hahn School of Nursing and Health 
Science at the University of San Diego (USD).  
The Study 
The study is about the concept of financial toxicity, which is a term that refers to the 
financial consequences of cancer treatment, which may include significant out of pocket (OOP) 
costs, loss of income and caregiver burden.  The study will help doctors, nurses and other health 
care providers better understand financial toxicity when experienced by cancer patients.  The study 
will include patients like you, who have completed or are taking cancer therapy given orally. 
The study involves you completing three surveys a) a demographics survey, b) a survey 
about your experience with financial toxicity during or after your cancer treatment, c) a survey 
about distress related to your cancer treatment.   It will take about 10-15 minutes for you to 
complete the surveys on-line. 
Inclusion/Exclusion Criteria 
The inclusion criteria for participants will be adult patients (21 years or older) who are 
Spanish or English speaking, have the ability to read English and have an initial diagnosis of these 
malignancies:  Breast cancer, head and neck cancer, Hodgkin’s Lymphoma, lung cancer leukemia, 
lymphoma, melanoma, multiple myeloma, myloproliferative neoplasms, pancreatic cancer, prostate 
cancer. Participants will need to have been prescribed by their oncologist a cancer treatment given 
orally as a component of their cancer treatment regimen.  The treatment given orally will be been 
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prescribed with the patient receiving treatment for at least 4 weeks. The participants’ health 
insurance coverage can include private health insurance or coverage by Medicare (Medicare Fee for 
Service (FFS), Medigap or Medicare Part C (Advantage). 
The exclusion criteria for study participants includes patients who have not been prescribed 
cancer treatment given orally (i.e. infusion only; radiation and/or surgery only) and those receiving 
in-patient cancer treatment. In addition, excluded study participants will be those covered by 
Medicaid or are those without health insurance coverage. 
Interested in joining this Study? 
If you would like more information about the study, here is a link to more information about 
the study: (Web Site #1)   You can also contact Ellen Carr, the study investigator, directly at e-mail: 
xxxxxxx; phone: xxxxxx. 
If you are interested in participating in the study, here is a link to the informed consent for 





Web Site #1 Content 
Study Synopsis 
Financial toxicity is an additional stress for patients being treated for cancer.  The study is 
about the concept of financial toxicity, which is a term that refers to the financial consequences of 
cancer treatment, which may include significant out of pocket (OOP) costs, loss of income and 
caregiver burden that occur when patients are undergoing treatment. The study will help doctors, 
nurses and other health care providers better understand financial toxicity when experienced by 
cancer patients.   
Oral medications for cancer are particularly expensive.  It is expected that more pricey oral 
medications will be approved as cancer treatments so there will be more patients who will deal with 
the financial toxicity of treatment. 
Therefore, Ellen Carr, an oncology nurse and doctoral student at the University of San 
Diego is studying financial toxicity and cancer patients who have been treated or are still in 
treatment with therapies given orally.  
The study will include patients like you, who have completed or are taking cancer therapy 
given orally. The Study Purpose and Aims of the study follow: 
Study Purpose: 
For adult participants who have received or are receiving treatment for hematologic and 
solid tumor malignancies given orally, to determine the relationship between participants’ 
experience of financial toxicity (FT), the participants’ perception of distress, and participants’ self-




Study Aims:  
1. To describe sociodemographic, clinical and financial characteristics, the experience 
of FT, perception of the level of distress, and adherence to treatment in a sample of adult 
participants who have received or are receiving treatment given orally for hematologic or solid 
tumor malignancies. 
2. To examine relationships between participant sociodemographic, clinical and 
financial characteristics, participants’ experience of FT, participants’ perception of distress, and 
participants’ adherence to treatment.    
3. To explore the likelihood that participant experience of FT predicts participant 
perception of distress and non-adherence to treatment given orally. 
FAQs about the Study 
1) What will I need to do to participate in the study? 
The study involves you completing three surveys a) a demographics survey, b) a survey 
about your experience with financial toxicity during or after your cancer treatment, c) a survey 
about distress related to your cancer treatment.   It will take about 10-15 minutes for you to 
complete the surveys on-line. 
2) Do I need to answer all questions on the surveys? 
No.  You can only give responses to questions that you choose to answer. 
3) Will I be paid to participate in the study? 





4) How will I hear about the results of the study? 
When the study results are complete and ready to be announced and published, Ellen can let 
you know.  (You will need to provide your contact information on your informed consent form so 
she can contact you.) 
Study Investigator’s contact information   
If you would like more information about the study, here is a link to more information about 
the study: (Web Site #1)   You can also contact Ellen Carr, the study investigator, directly at e-mail: 
xxxxxxx; phone: xxxxxx. 
Instructions to join the Study 
If you are interested in participating in the study, here is a link to the informed consent for 
the study, then after confirm acceptance of the informed consent, Ellen will contact you via your e-





Web Site #2 Content 
 
Study Synopsis (repeat from Web site #1) 
Financial toxicity is an additional stress for patients being treated for cancer.  The study is 
about the concept of financial toxicity, which is a term that refers to the financial consequences of 
cancer treatment, which may include significant out of pocket (OOP) costs, loss of income and 
caregiver burden that occur when patients are undergoing treatment. The study will help doctors, 
nurses and other health care providers better understand financial toxicity when experienced by 
cancer patients.   
Oral medications for cancer are particularly expensive.  It is expected that more pricey oral 
medications will be approved as cancer treatments so there will be more patients who will deal with 
the financial toxicity of treatment. 
Therefore, Ellen Carr, an oncology nurse and doctoral student at the University of San 
Diego is studying financial toxicity and cancer patients who have been treated or are still in 
treatment with therapies given orally.  
The study will include patients like you, who have completed or are taking cancer therapy 
given orally. The Study Purpose and Aims of the study follow: 
Study Purpose: 
For adult participants who have received or are receiving treatment for hematologic and 
solid tumor malignancies given orally, to determine the relationship between participants’ 
experience of financial toxicity (FT), the participants’ perception of distress, and participants’ self-




Study Aims:  
1. To describe sociodemographic, clinical and financial characteristics, the experience 
of FT, perception of the level of distress, and adherence to treatment in a sample of adult 
participants who have received or are receiving treatment given orally for hematologic or solid 
tumor malignancies. 
2. To examine relationships between participant sociodemographic, clinical and 
financial characteristics, participants’ experience of FT, participants’ perception of distress, and 
participants’ adherence to treatment.    
3. To explore the likelihood   that participant experience of FT predicts participant 
perception of distress and non-adherence to treatment given orally. 
 
Instructions to complete the Informed Consent 
Please follow the link to the Informed Consent form: 
Informed Consent: 
Introduction:  You are invited to be a participant in a research study conducted by Ellen Carr, RN.  
Ellen is a clinical oncology nurse.  She is also a doctoral student at the Hahn School of Nursing and 
Health Science at the University of San Diego (USD).    
The study is about the concept of Financial Toxicity.  Financial Toxicity refers to the 
financial consequences of cancer treatment, which may include significant out of pocket (OOP) 
costs to you and your family, loss of income and patient and caregiver burden.  The study will help 
doctors, nurses and other health care providers better understand financial toxicity when 
experienced by cancer patients.  This study will include patients like you, who have completed or 
are taking cancer therapy given orally. 
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Purpose of the study:  
For patients receiving treatment for hematologic and solid tumor malignancies given orally, 
the purpose of this study is to determine the relationship between the patient’s experience of 
financial toxicity, the patients’ perception of their level of distress and whether patients went ahead 
and took or completed their prescribed therapy given orally. 
Procedures:   
From an on-line survey that you can complete at your convenience, you will be asked about 
your experience with financial toxicity during the period when you were (or still are) taking your 
cancer therapy given orally.  Specifically, you will be asked to complete three brief surveys about 
the financial burden while you are on the therapy, any distress related to the financial burden when 
you were on the therapy and if the financial burden caused you to stop taking your therapy or take 
part of your therapy. Completing all the questions on the three surveys will take about 10-15 
minutes.  You can choose to not answer some of the questions. 
Potential Risks and Discomforts:   
The questions on the survey may cause you to feel sad or mad.  You can choose not to 
answer any questions.  You also may stop answering questions at any time. 
Anticipated Benefits to You:   
You will not receive any direct benefit from participating in the study.   There is no 
compensation for participating in this study. However, after completing the survey, you may feel 




Anticipated Benefits to Others:   
The study results will help doctors, nurses and other health care providers better understand 
financial toxicity when experienced by cancer patients.  With that knowledge, ways to lessen the 
financial burden for patients and their caregivers can be developed. 
Privacy/Confidentiality:    
Your responses to the surveys will be kept confidential.  This informed consent and any 
other identifying information will be kept separate from the survey results.  All study information 
will be kept in a locked, secured location.   Your survey results will be assigned a unique 
identification number. Any study identification number assigned to you will only be known by 
Ellen, the study investigator, and her dissertation committee; they are the only people who will have 
access to your study identification number.  Any report of the study results will not identify you by 
name or your identification number. 
Withdrawal from Study:  
Your participation in the study is entirely voluntary.   If you participate in the study, your 
participation will not affect your current or future cancer care.  You can withdraw from the study at 
any time, either during or after your participation in the study, with no negative consequences.  If 
you withdraw from the study, your survey results will be destroyed. 
Your Rights:   
You can choose to participate in the study.  If you do participate, you can withdraw from the 
study at any time without consequences.   You are not waiving any legal rights if you choose to 
participate in the study.   If you have questions about your rights as a participant of this study or if 
you have concerns about the study and want to discuss those with someone other than Ellen Carr, 
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you can contact the University of California Office of Research Protection, phone:  xxxx  address: 
xxxxx 
You may request a copy of the study’s final results by indicating your interest at the end of 
this consent.  And after this study if you are interested in being contacting by the investigator again 
about a follow-up study about financial toxicity and cancer patients, please check the box below.  
Investigator Identification:    
Ellen Carr, RN, is the study investigator.  If you have questions for Ellen, you can contact 
her via this e-mail link:  xxxxxx.   You can also contact her at 619-922-3903. 
+++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
Participant Signature: 
By clicking the accept key below, you are confirming that you have read this document, you 
understand the purpose of the study and you have had the opportunity to ask questions about 
proceeding to participate in the study.   
Name 
Signature (key click)        Date stamp: 
e-mail address: 
NOTE: Based on your clicking the accept key, Ellen Carr, the study’s investigator, will now contact 
you by your e-mail above with a link to the study’s questionnaires.  By completing the study’s 






By clicking the key below, I confirm that I have provided an explanation of the study to the 
participant and have answered his/her questions.   By the participant confirming that he/she has read 
this document, the participant understands the purpose of the study and has had the opportunity to 
ask questions, thereby giving asset/consent to proceed to participate in the study.   
Name 
Signature (key click)        Date stamp: 
 
++++++ 
Further contact from Ellen Carr about study results or follow-up study: 
 Please send a summary of the study results to: 
Name 
e-mail address 
 I am not requesting a summary of the study results 
 I am willing to be contacted by Ellen Carr, the study investigator, about a follow-up 










Instrument # 1: Demographic Questionnaire 
 General 




2) I am 
 < 50 years old 
 50-64 years old 
 >65 years old 
 
3) My living status is 
 Married 
 Live with a domestic partner in the same household 
 Live as a single 
 Live in a community setting (i.e. with roommates) 
 
4) Highest level of education 
 < 12th Grade 
 12th Grade 
 Some college 
 Completed college 
 Some or complete graduate school 
 
Cancer Diagnosis 
1) I am diagnosed with cancer or malignancy 
 Yes 
 No 
 Don’t know 
 
2) If yes to #1 above, my cancer diagnosis is 
(Open text; optional response) 
 
3) Stage at Diagnosis 
 Stage 1 
 Stage 2 
 Stage 3 






4) Prescribed oral cancer therapy (drugs, dose, frequency) 
(Open text) 
 




6) Because of issues of cost or expense of the cancer therapy (given orally), when prescribed 
the therapy I: 
 Stayed on or completed the therapy 
 Temporarily stopped taking the therapy 
 Never started the therapy 
 
7) Because of the cost or expense of the cancer therapy (given orally), did you decide to 
stop taking any other prescribed medications or treatments for your other conditions?  (i.e. 
examples of other conditions, which you are receiving treatments: high blood pressure, 




8) For other prescribed medications you are taking (see #7), did you decide to take some of 
those prescribed medications at their prescribed doses rather than your cancer therapy (given 





9) For other prescribed medications you are taking (see #7), did you decide to take lower or 
less doses of medications rather than your cancer therapy (given orally) because of the cost 















2) If yes to #1, please check your current insurance coverage? 
 Private Insurance (not Medicare) 
 Medicare 
 Medigap 
 Medicare Part C (Advantage) 
 




4) If yes to #3, which plan? 
 
 Private insurance prescription plan 
 Medicare Part D 
 
Finances 
1) I am employed 
 Fulltime 
 Part-time (<20 hours/week) 
 Not employed 
 











4) My income supports 
 Myself only 
 Myself and committed partner 
 Myself, committed partner and others 
 
5) During the last tax year, my gross income was 





6) To cover the cost of my cancer treatment given orally, I am responsible to pay for: 
 <20% of the cost 
 20-50% of the cost 
 50-100% of the cost 
 
7) To cover the cost of my treatments, I received monetary help from pharmaceutical 




8)  If yes to #7, the monetary help I received per treatment was approximately: 
 < 20% 
 20-50% 
 50-100% 
 Don’t know 
 
9) During my cancer treatment, other treatment-related expenses that I paid for out-of- pocket 
include or included: 
 transportation 
 hotel costs 
 lost wages 
 child care 
 over the counter medication 
 Other (open text) 
 









Instrument #2: Comprehensive Score for Financial Toxicity (COST) 
 
Source: deSouza J, Yap B, Wroblewski K, Blinder V, Araujo F, Hlubocky F, et al. Measuring 
financial toxicity as a clinically relevant patient-reported outcome: The validation of the 











Source: NCCN: Retrieved from 
https://www.nccn.org/patients/resources/life_with_cancer/pdf/nccn_distress_thermometer.pdf 
(Used with permission: NCCN)  
 
 
 
